Signed By [CONTACT_232389]/Time (UTC)APPROVALSCONFIDENTIAL  
DOCUMENT/RECORD  
 
This document/record is electronically controlled; printed copi[INVESTIGATOR_42546]. 
System of Record: Regulatory Affairs Domain  
Document Name [CONTACT_239107], Rachael
05/02/2022 18:50:26
1.0
Medical Writer
05/02/2022 12:48:16
Randall, Taryn
CSPOT Clinical Iinvestigation Plan V4.0 29APR2022
Clinical Quality/Compliance
Rhoads, Neysa
05/02/2022 18:54:48
Aso, Joy
05/02/2022 16:32:18
05/02/2022 18:50:27
Gielkens, Manon
04/29/2022 20:02:57
Rose, Rachael
Tinsley, Jennifer
Document Approver
Clinical Study Manager (CSM)
04/30/2022 01:07:41
Zimmerman, Patrick
05/02/2022 12:48:17
Randall, Taryn
Palm, Kaitlyn
04/29/2022 20:50:57
04/29/2022 21:18:52
Safety
05/02/2022 18:50:[ADDRESS_289909]
Rose, Rachael
Regulatory
CSPOT Clinical Iinvestigation Plan V4.0 29APR2022
Document Author

CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  1 of 88 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template   
  
 
 
 
 
Clinical  Investigation Plan  
Clinical  Investigation  Plan/Study  Title  Conduction  System  Pacing Optimized  Therapy  
(CSPOT)  
Clinical  Investigation  Plan  Identifier  MDT20029  
Study  Product  Name  [CONTACT_239108]  (an un-modified CRT  
device  with  off-label  use  lead placement)  
Sponsor/Local  Sponsor  and EU Legal  
representative  Medtronic, Inc 
[ADDRESS_289910]  NE 
Mounds  View,  MN  U.S.A. [ZIP_CODE]  
Phone: +[PHONE_4970]  
 
Medtronic, Bakken Research  Center B.V.  
Endepolsdomein  5, 6229 GW  Maastricht,  
The  Netherlands  
Phone: [PHONE_4973]  
Document  Version  4.0, 29-Apr -[ADDRESS_289911]  know  that it is 
confidential  and that it may not be  further  disclosed by  [CONTACT_476].  

CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289912] Research Organizations  ........................................................................................... 8 
1.3. Principal  Investigator  ............................................................................................................ 8 
2. Glossary  .......................................................................................................................................... 9 
3. Synopsis  .............................................................................................................................  12 
Inclusion Criteria  ....................................................................................................................... 14 
Exclusion Criteria  ......................................................................................................................  15 
4. Introduction  ........................................................................................................................  17 
4.1 Background  ....................................................................................................................... 17 
4.2 Purpose  ............................................................................................................................  18 
5. Objectives and/or  Endpoints  ................................................................................................ . 19 
5.1 Objectives  ........................................................................................................................  19 
5.1.1  Primary  Objective(s)  ...........................................................................................................  19 
5.1.2  Secondary  Objective(s)  .......................................................................................................  [ADDRESS_289913]  Description  .............................................................................................................  22 
7.1 General  ............................................................................................................................ 22 
7.1.1  Medtronic Compatible CRT -D/CRT -P Devices  ..................................................................  24 
7.1.2  ECG Belt  System .................................................................................................................  25 
7.1.3  Millar  Pressure  Catheter  and Connection Cable  ................................................................ . 25 
7.1.4  Cardiotek  EP System  and 12 Lead ECG  system ................................................................ . 25 
7.1.5  Threshold Cables .................................................................................................................  25 
7.1.6  Medtronic External  Pacer  .................................................................................................... 25 
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289914]  Return  .................................................................................................................. 28 
8. Study  Site  Requiremen ts ...................................................................................................... 28 
8.1 Investigator/Investigation Site  Selection  ...............................................................................  [ADDRESS_289915] Enrollment  ............................................................................................................. 30 
9.3 Inclusion Criteria  ................................................................................................................  30 
9.4 Exclusion Criteria  ...............................................................................................................  30 
10. Study  Procedures  .............................................................................................................  31 
10.1 Schedule  of Events  and  Data Collection  .................................................................................  31 
10.2 Prior a nd Concomitant  Medications/Therapi[INVESTIGATOR_014]  .......................................................................  [ADDRESS_289916] Consent  ................................................................................................................  32 
10.4 Enrollment  ........................................................................................................................  34 
10.5 Baseline  ...........................................................................................................................  34 
10.6 CRT -D/CRT -P Implant  ........................................................................................................ [ADDRESS_289917] Chooses  to Exit (i.e., Revokes Consent)  ................................................................  42 
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289918]  ..........................................................................................  42 
10.8 Device Interrogation ...........................................................................................................  42 
10.9 System  Modification  ...........................................................................................................  42 
10.10 Medication Assessment  ...............................................................................................  43 
10.11 Assessment  of Safety  ..................................................................................................  43 
10.12 Recording  Data ...........................................................................................................  43 
10.13 Deviation Handling  ......................................................................................................  45 
11. Risks and  Benefits  ............................................................................................................ 46 
11.1 Potential  Risks ...................................................................................................................  46 
11.2 Risk  Minimization  ...............................................................................................................  47 
11.3 Potential  Benefits  ..............................................................................................................  50 
11.4 Risk -Benefit Rationale .........................................................................................................  50 
12. Adverse Events and  Device  Deficiencies  ..............................................................................  50 
12.1 Adverse Events  .................................................................................................................  50 
12.2 Device Deficiency  ..............................................................................................................  50 
12.3 Processi ng Updates  and  Resolution  ....................................................................................... 51 
12.4 Definitions/Classifications  ................................................................................................... [ADDRESS_289919]  Complaint Reporting  ...............................................................................................  62 
13. Data Review  Committees  ..................................................................................................  63 
13.1 Clinical  Events  Committee  ................................................................................................... 63 
14. Statistical  Design and  Methods  ..........................................................................................  64 
14.1 Genera l Aspects  of Analysis  ................................................................................................ . 64 
14.2 Analysis Execution  ............................................................................................................. 65 
14.3 Interim  Analysis  .................................................................................................................  65 
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  5 of 88 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template   
 14.4 Primary Objectives  ............................................................................................................. 65 
14.4.1  Primary  Objective #1 ..........................................................................................................  65 
14.4.2  Primary  Objective #2 ..........................................................................................................  65 
14.5 Secondary  Objectives  .........................................................................................................  66 
14.5.1  Secondary  Objective #1 ..................................................................................................... 66 
14.5.2  Secondary  Objective #2 ..................................................................................................... 66 
14.5.3  Secondary  Objective #3 ..................................................................................................... 67 
14.5.4  Secondary  Objective #4 ..................................................................................................... 67 
14.5.5  Secondary  Objective #5 ..................................................................................................... 67 
14.6 Ancillary Objective  (Adverse  Events)  .....................................................................................  67 
14.7 Additional  Data Collection  ................................................................................................... 68 
14.8 Sample Size  Determination ..................................................................................................  68 
15. Ethics  ............................................................................................................................. 68 
15.1 Statement(s)  of Compliance  ................................................................................................  [ADDRESS_289920]  Access  to Source  Data/Documents  ............................................................................. 71 
16.
4 Confidentiality  ...................................................................................................................  71 
16.5 Liability/Warranty/Insurance Information  ...............................................................................  71 
16.5.1  Warranty  ..............................................................................................................................  71 
16.5.2  Insurance  (Europe) ..............................................................................................................  [ADDRESS_289921]  Retention  ...............................................................................................................  72 
16.7.1  Investigator  Records  ...........................................................................................................  72 
16.7.2  Sponsor  Records  .................................................................................................................  73 
16.8 Reporting  Requirements  .....................................................................................................  74 
16.8.1  Investigator  Reports  ...........................................................................................................  74 
16.8.2  Sponsor  Reports  .................................................................................................................  77 
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  6 of 88 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template   
 16.9 Publication and  Use of Information  ........................................................................................  78 
16.9.1  Publication  Committee .......................................................................................................  78 
16.9.2  Management of Primary, Secondary, and Ancillary  Publications  ........................................  79 
16.9.3  Criteria  for Determining Authorship  ...................................................................................  79 
16.9.4  Transparency  ......................................................................................................................  80 
16.10 Suspension or Early Termination  ....................................................................................  80 
16.10.1  Planned Study  Closure  .................................................................................................... 80 
16.10.2  Early  Termination  or Suspension  .................................................................................... 80 
16.10.3  Procedures  for Termination  or Suspension .................................................................... 81 
17. References  ...................................................................................................................... 82 
18. Appendices  .....................................................................................................................  83 
18.1 Informed  Consent  Template  ...............................................................................................  83 
18.2 Data Collection Elements  (Electronic  Case  Report  Forms)  ......................................................  [ADDRESS_289922]  (FAL) ................................................................................  84 
18.7.1  Observed  Adverse  System  Effects  in Previous  Clinical  Studies  and Adverse  Events  
Repor
ted  in Literature  ........................................................................................................................  84 
19. Version History  ................................................................................................................  86 
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289923] information  will  be sent  to the  sites  as needed.  
 
Table  1: Sponsor  Contact  [CONTACT_239013]/US  contact  
[CONTACT_239014],  Pr. Clinical  Research  Specialist  
 
 
Europe  clinical  study  leader/OUS  contact  
[CONTACT_239015], Clinical Research  
Specialist  
 
 
Monitoring  Contacts  
Worldwide  monitoring  leader/US  contact  
[CONTACT_239016],  Clinical  Monitoring  Manager  
 
 
 
Monitoring  leader  Europe  
Anja  Hesse,  Prin.  Clinical  Research  Monitor  

CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289924] to  change  during the  clinical  study.  
Periodic updates  to CRO information  will  be sent to the  sites  as needed.  
 
Table  2: CRO  Information  
 
Contact  [CONTACT_239017]  
[ADDRESS_289925]  Phone:  [PHONE_4974]  801- [ADDRESS_289926]  Fax:  [PHONE_4974]  801 -0243  • Development  of study  electronic  case  report  forms,  edit  
checks,  and study  management  reports.  
• Review of electronic  case  report  forms,  management  of 
discrepancies of data  collection,  and coding  of deviations.  
 
 
1.3. Principal  Investigator  
[INVESTIGATOR_238984].  Periodic updates  to Principal  Investigator [INVESTIGATOR_238985].  
 
Table  3: Overall  Study  Principal  Investigator  [INVESTIGATOR_238986], MD  University of Chicago  
119th E 18th St 
Chicago,  IL [ZIP_CODE] 
United  States  
 

CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289927] Research Organization  
CRT -D Implantable  Cardioverter Defibrillator with Cardiac  
Resynchronization Therapy  
CRT -P Implantable  Pulse  Generator with Cardiac  
Resynchronization Therapy  
CRF  Case Report Form  
CSP  Conduction  System  Pacing  
CSPOT  Conduction  System  Pacing,  Optimized  Therapy  
CTA  Clinical  Trial  Agreement  
CV Curriculum  Vitae  
DD Device Deficiency  
DMC  Data Monitoring  Committee  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289928]  
eCRF  Electronic  Case  Report Form  
EC/IRB/HREB/Ethics Board  Ethics  Committee  
ECG Belt  Electrocardiogram  Belt  
FAL  Foreseeable  Adverse  Events  List  
FD Financial  Disclosure  
FDA  Food  and  Drug  Administration  
FDAAA  Food  and  Drug  Administration Amendments  Act  
GCP  Good Clinical  Practice  
HIPAA  Health Insurance  Portability and  Accountability  Act  
IB Investigator Brochure  
IC Informed  Consent  
ICD  Implantable  Cardioverter Defibrillator  
ICH  International  Conference of Harmonization  
IDE  Investigational  Device Exemption  
IFU  Instructions  For Use  
IPG  Implantable  Pulse  Generator  
IVCD  Intraventricular Conduction  Delay  
LBBB  Left  Bundle  Branch  Block  
LBBP  Left  Bundle  Branch  Pacing  
LV Left  Ventricle  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289929]  Medical  Device  Regulation  (EU)  
MedDRA  Medical  Dictionary for Regulatory Activities  
MHRA  Medicines  and  Healthcare  products  Regulatory  
Agency ([LOCATION_006])  
MI Myocardial  infarction  
PHI  Protected  Health Information  
RA Right Atrium  
RBBB Right Bundle Branch Block  
RPI  [INVESTIGATOR_238987]-Delay  Ventricle  to Ventricle  Delay  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  12 of 88  
  
 
3. Synopsis  
 
  Title  Conduction  System  Pacing Optimized  Therapy  (CSPOT)  
Clinical  Study  Type  Prospective, non -randomized, multi -center, global, feasibility  clinical  study  
Product  Name  [CONTACT_239108]  (an un-modified CRT device  with  off label  use  lead  
placement)  
Sponsor  Sponsor:  
Medtronic, Inc 
[ADDRESS_289930]  NE 
Mounds  View,  MN  U.S.A. [ZIP_CODE]  
Phone: +[PHONE_4970]  
 
Local  Sponsor:  
Medtronic, Bakken Research  Center B.V.  
Endepolsdomein  5, 6229 GW  Maastricht,  
The  Netherlands  
Phone: [PHONE_4973]  
External  
Organizations  Cognizant  Technology  Solutions  
[ADDRESS_289931] Phone: +x [PHONE_4971]  
Direct Fax: +x  [PHONE_4972] 
Indication  under  
investigation  The  CSPOT pacing system  is utilizing a market  approved  CRT device  and market  
approved  leads  to compare  off-label  methods  of pacing:  CSP (LBBP)  and the  
combination  of CSP  +LV.  
Investigation  
Purpose  The  purpose  of the  CSPOT study  is to determine  the  best mode  of CRT pacing for 
different populations of CRT  patients, comparing traditional  BiV, CSP -only, and  
CSPOT (CSP+LV)  pacing.   Additionally, safety  of the  system  will  be assessed.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289932]/System   
 
 
 
 
 
 
 
Power  isolation  transformer  
 
 
as needed  
 
 
 
 
 
Cardiotek  EP Recording  System  
Study  Objective  Primary  Objectives:  
 
1. Compare  the  electrical  synchronization  response  of CSPOT pacing  
configuration  to CSP -only  and traditional  CRT  (See  section  10.7.1)  in 
patients  undergoing a CRT implant, using the  SDAT ECG -belt metric.  
2. Compare  the  hemodynamic response  of a CSPOT pacing configuration  to 
CSP -only  and traditional  CRT  in patients undergoing a CRT  implant, using  
the  contractility  parameter positive  LV dP/dt max.  
 
Secondary Objectives:  
 
1. For  each  pacing configuration  (CSP -only, traditional  CRT,  and CSPOT),  
summarize  the  improvement in the ECG  Belt  SDAT  measurement 
relative to baseline at implant, for  the  following  subpopulations:  
a. Subjects  with  QRS  width  < 150ms and those  with  QRS  width  >= 
150ms,  as measured  by 12-lead ECG  at implant  
b. Subjects  with  pure  LBBB and those  with  other conduction  disorders  
c. Subjects  with  ischemic  cardiomyopathy  and those  with  non - 
ischemic  cardiomyopathy  
2. For  each  pacing configuration  (CSP -only, traditional  CRT,  and CSPOT),  
summarize  the  improvement in the  contractility  parameter positive LV 
dP/dt max  relative to baseline at implant,  for the  following 
subpopulations:  
a. Subjects  with  QRS  width  < 150ms and those  with  QRS  width  >= 
150ms,  as measured  by 12-lead ECG  at impla nt 
           
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  14 of 88  
  
 c.    Subjects  with  ischemic  cardiomyopathy  and  those  with  non - 
ischemic  cardiomyopathy  
3. Characterize  the  chronic clinical  response  from  CSPOT pacing by  
[CONTACT_239018] 6 months  
4. Characterize  the  chronic clinical  response  from  CSPOT pacing by  
[CONTACT_239019] 6 months  
5. Characterize  the  chronic clinical  response  from  CSPOT pacing by  
[CONTACT_239020]  [1, 2] at [ADDRESS_289933]  will  be programmed in  their  patient- 
specific CSPOT (CSP+LV)  configuration  and patients will  be followed up for 6 
months  or until  official  study  closure, defined  as when Medtronic and/or  regulatory  
requirements  have  been  satisfied per  the  Clinical  Investigation  Plan  and/or  by a 
decision  by [CONTACT_239021], whichever occurs  first.   
 
 All adverse  
events (AEs)  will  be collected throughout the study  duration  of a subject’s  
participation  in the  study, beginning at the  time  of informed consent.  
Sample  Size  The  study  is expected to  be conducted  at up to 12 sites in the  [LOCATION_002]  and  
Europe  and up to 60 subjects  will  be enrolled with  no more  than  15 subjects  
enrolled per  site.  
Inclusion/Exclusion  
Criteria  Inclusion  Criteria  
• Patient is willing and able  to provide  written  informed consent  
• Subject is  at least  18 years of age  
• Patient is willing and able  to comply  with  the  protocol, including follow -up 
visits  
• The  patient’s medical  records  must  be accessible  by [CONTACT_239022] -up period  
• Standard  CRT -D or CRT -P indications, with  a preference  for IVCD  and non - 
LBBB patients,  where  LBBB is defined  according to  Strauss  criteria.  
• De-novo  CRT implant, including upgrade  from  pacemaker or ICD  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  15 of 88  
  
  Exclusion Criteria  
• Subject has  persistent  or permanent AF (Atrial  Fibrillation)/AFL (Atrial  
Flutter)  
• Subject has  2nd  or 3rd degree  AV (Atrioventricular)  Block  
• Subject has  RBBB  with  no additional  conduction  block  
• Subject has  intrinsic (non -paced)  QRS  width  less than  or equal  to 120  
ms 
• Subject experienced MI  within  40 days  prior  to enrollment  
• Subject underwent valve  surgery, within  90 days  prior  to enrollment  
• Subject is  post heart transplantation  or is actively  listed on  the  
transplantation  list 
• Subject is  implanted  with  a LV assist device  
• Subject has  severe  renal  disease  
• Subject is  on continuous  or uninterrupted  infusion  (inotropic)  therapy  
for heart failure  
• Subject has  severe aortic  stenosis  (with  a valve  area  of <1.0 cm or 
significant valve  disease  expected  to be operated within  study  period)  
• Subject has  severe aortic  calcification  or severe  peripheral  arterial  
disease  
• Subject has  complex  or repaired  congenital heart disease  
• Subject has  mechanical  heart valve  
• Pregnant or  breastfeeding woman  (pregnancy  test  required for  woman  
of child- bearing potential  and who  are  not  on a reliable  form  of birth  
regulation  method  or abstinence)  
• Subject is  enrolled  in another  study  that could confound the results of 
this  study  without documented  pre -approval  from  Medtronic study  
manager   
Study  Procedures  
and Assessment    
 
 
STUDY  PROCEDURE  
 
Baseline  
(occur  within  30 
days  prior to 
enrollment)  
 
Implant  
(occur  within  30 
days  after 
enrollment)  
 
6 month follow  
up and  Study  
Exit   
  Patient Informed Consent  X    
  Inclusion/Exclusion  Assessment  X    
  Demographics  X    
  Medical History  X    
  Physical  Exam  X  X  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  16 of 88  
  
  Medication  Assessment  X X 
Baseline  12- Lead ECG  (within  60 days prior  to X 
enrollment/consent)  
Baseline  Echocardiography  including LVEF  and  LVESV  (within  X 
60 days prior  to enrollment/consent)  
NYHA  X X 
ECG  Belt  X 
Lead Placement  X 
CSPOT Research  System  Protocol  X 
Insertion  procedure information  X 
Fluoroscopic  Images of final  LBBP  lead placement  X 
Patient Global Assessment  X 
6 Month Echocardiography  including LVEF  and  LVESV  (within  X 
30 days prior  to visit)  
6 Month 12- Lead ECG  (within  30 days prior  to visit)  X 
Final  device  programming  X X 
Initial  and  Final  Device  Interrogation  (with  either  initial  or final  X X 
interrogate ALL) and  collect  .pdd file 
Adverse  Events  
Hospi[INVESTIGATOR_238988] (AEs)  and device  deficiencies  will  be collected throughout the  
study  duration  of a subject’s  participation,  beginning at the  time  of informed  
consent. An  independent Clinical  Event Committee  (CEC)  will  conduct a medical  
review  and adjudicate  at a minimum  all CRT -D/CRT -P system  and procedure - 
related adverse  events, all  CSPOT system  and procedure -related adverse  events,  
all cardiovascular  related  AEs  (regardless of seriousness),  all SAEs and all  AEs  with  a 
fatal  outcome.  The  CEC will  consist of non -Medtronic employed  physicians  that  
are  not participating investigators  for the  study.   
Statistics   A sample  size  of up to 60 subjects  will  be enrolled to  determine  the  pacing  
configuration  that provides better acute  electrical  synchrony and hemodynamic  
response.  
Additional  sub -analyses will  be performed to  assess whether sub -populations 
derive  benefit from  different configurations.   
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289934] -of-care  therapy  for heart failure  patients with  wide  QRS  is cardiac  
resynchronization  therapy  (CRT), which  is commonly  accomplished through  biventricular pacing.  His  
Bundle  pacing may  benefit  some  CRT patients  as a replacement  for biventricular  pacing [ 3-6 ]. 
However,  His  Bundle  pacing will  not resynchronize  some  CRT patients  that have  conduction  block  
distal  to the  His  Bundle  pacing location. In an effort to  increase  the  benefit  of His Bundle  pacing for  CRT  
patients, three  studies  suggested that the combination  of His  Bundle  pacing with  LV pacing  
(sometimes called  “HOT -CRT”)  provided improved  clinical  outcome  [7-9 ]. Nevertheless, His  Bundle  
pacing frequently  suffers from  high  and unstable  pacing thresholds and remains  a challenging 
procedure.  
 
A different form  of conduction  system  pacing (CSP),  left  bundle -branch  pacing (LBBP),  was  introduced  
in 2017 [10]. LBBP has  lower and more  stable  pacing thresholds than  His  Bundle  pacing and is  generally  
considered to  be a simpler procedure.   Several  studies  have  shown  that LBBP  is promising  as an 
alternative  to BiV  pacing in  CRT  patients  [11-13].  However,  it appears  that, like His  pacing,  some  CRT  
patients  will  not receive adequate  resynchronization  from  LBBP  alone.  These  CRT patients may  have  
more  diffuse  conduction  disease,  such  as a combination  of left  bundle -branch  block  (LBBB)  and 
intraventricular conduction  delay  (IVCD). Two  studies  have  provided pi[INVESTIGATOR_238989] (now  referred  to as “CSPOT”  pacing)  may  improve  resynchronization  in some  
LBBP  patients [12, 13]. These  s tudies  encourage  further  study  of LBBP  and CSPOT  pacing  in CRT  
patients, with  emphasis on comparing the degree  of resynchronization  from  each  kind of pacing  
therapy  and on  determining  the  types of patients that benefit  from  each  kind of pacing  therapy.  A 
summary/evaluation  of the  results of the  pre -clinical  testing can  be found in  the  IB (Investigator 
Brochure).  
 
The  CSPOT study  therefore aims  to compare three  modes  of resynchronization  pacing:  1) traditional  
CRT (BiV  or LV -only  pacing), 2) LBBP, and 3) CSPOT (CSP+LV).   The  study  will  collect three acute  
measures of resynchronization: 1) Mechanical  measures of resynchronization  via LV pressure,  2) 
Electrical  measures of resynchronization  via the  ECG  Belt, and 3) Electrical  measures of 
resynchronization  via the  12-lead ECG.  
 
The  schematic  below  provides  an overview of the  CSPOT  system.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  18 of 88  
  
 
 
Figure  1: CSPOT Research  System  
 
 
 
4.[ADDRESS_289935]  mode  of CRT pacing for different  populations of CRT  patients, comparing traditional  CRT (BiV or 
LV- only  paci ng), CSP -only, and CSPOT  pacing.  
 
The  CSPOT (Conduction  System  Pacing Optimized  Therapy) Research  System  is being developed to  
support pre -market  research  comparing the  acute effects of several  different modalities  of cardiac  
resynchronization  pacing  and to collect  data  for use  in future  algorithm  development.  CSP, specifically  
LBBP,  may  provide  superior  resynchronization  compared to  traditional  CRT  pacing.   A subset  of 
patients  may further  benefit from  the  combination  of traditional  LV pacing  and CSP.   The  CSPOT  
Research  System  will  allow  collection  of ECG, EGM, LV pressures and ECG  Belt  dyssynchrony metrics  
during periods  of traditional  CRT  pacing (BiV  or LV-only pacing), CSP -only  (i.e.  LBB)  pacing  and CSP+ LV 
pacing.   Findings  from  this  feasibility  study  may be used  as design  inputs  in developi[INVESTIGATOR_007] a new system  
based on  this  technology.  No long -term  data  using the  research  system  will be collected.  
The  CSPOT Research  System  is investigational  and not  intended for market release.  
 
 
 
as needed  
 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  19 of 88  
  
5. Objectives  and/or  Endpoints  
 
5.1 Objectives  
This  prospective,  non -randomized, multi -center, global, feasibility  clinical  study  is designed  to assess  
augmentation  of electrical  resynchronization  as measured  by [CONTACT_90660] -belt metrics  and 12-lead ECG, and  
to assess augmentation  of contractility  as measured  by [CONTACT_239023]/dt max  across  LV pacing site(s)  
in patients  indicated for CRT.  
 
Thereto, the SDAT metric  from  ECG  Belt  and the  force  of contraction  during  CSP or  CSPOT  pacing will  
be compared to  that of standard  CRT  pacing.   
 In addition, the  chronic  
electrical  and clinical  response  will  be investigated. Rationale  for study  design  is to aim  for maximizing  
the  acute electrical  and hemodynamic response  on a per -patient basis, therefore  the  primary  endpoint 
is written  to satisfy  comparing the response  of CSPOT, the  investigational  system  to traditional  CRT  
pacing.  
5.1.1    Primary Objective(s)  
The  primary  objectives  of the  study  are:  
 
1. Compare  the  electrical  synchronization  response  of CSPOT pacing configuration  to CSP -only  
and traditional  CRT (See  section  10.7.1)  in patients  undergoing a CRT implant,  using the  SDAT  
ECG- belt metric.  
2. Compare  the  hemodynamic response  of a CSPOT pacing configuration  to CSP -only  and 
traditional  CRT  in patients undergoing a CRT  implant,  using the  contractility  parameter positive 
LV dP/dt max.  
 
5.1.2  Secondary  Objective(s)  
The  secondary  objectives  of the  study  are:  
 
1. For  each  pacing configuration  (CSP -only, traditional  CRT,  and CSPOT),  summarize  the 
improvement in the  ECG Belt  SDAT measurement  relative to baseline at implant, for  the  
following subpopulations:  
a. Subjects  with  QRS  width  < 150ms and those  with  QRS  width  >= 150ms,  as measured  by 
12-lead ECG  at implant  
b. Subjects  with  pure  LBBB and those  with  other conduction  disorders  
c.    Subjects  with  ischemic  cardiomyopathy  and those  with  non -ischemic cardiomyopathy  
2. For  each  pacing configuration  (CSP -only, traditional  CRT,  and CSPOT),  summarize  the 
improvement in  the  contractility  parameter positive LV dP/dt max  relative to baseline at 
implant, for  the  following subpopulations:  
a. Subject s with  QRS  width  < 150ms and those  with  QRS  width  >= 150ms,  as measured  by 

[CONTACT_239024]  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  20 of 88  
 12-lead ECG  at implant  
b. Subjects  with  pure  LBBB and those  with  other conduction  disorders  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  20 of 88  
  
c.    Subjects  with  ischemic  cardiomyopathy  and those  with  non -ischemic cardiomyopathy  
 
3. Characterize  the  chronic clinical  response  from  CSPOT pacing by  [CONTACT_239025] 6 months  
4. Characterize  the  chronic clinical  response  from  CSPOT pacing by  [CONTACT_239026] 6 months  
5. Characterize  the  chronic clinical  response  from  CSPOT pacing by  [CONTACT_239027]  [1, 2] at [ADDRESS_289936]  data  for use  in future  algorithm  development.   The  study  may 
enroll  up to 60 subjects  at up to 12 sites in the  US,  [LOCATION_006], and Europe  with  no more  than  15 subjects  
enrolled  per  site.  Study  subjects  will  be followed for  6 months  or until  official  study  closure,  defined  as 
satisfaction  of Medtronic  and/or  regulatory  requirements  (per  the  Clinical  Investigation  Plan)  and/or  by 
a decision  by [CONTACT_239028], whichever occurs  first.  
 
All adverse  events (AEs)  and device  deficiencies  will  be 
collected throughout the study  duration  of a subject’s  participation  in the  study, beginning at t he time  
of informed consent.  
Following consent, subjects  will  under g o a baseline  assessment followed by  [CONTACT_239029],  which  will  include  the  CSPOT Study  Protocol.  Each patient will  serve  as their  own  control.  
This  will  be considered the  acute  phase.  Following the  CSPOT study  protocol  procedure, the CRT - 
D/CRT -P device  will  be implanted.  Each  subject will  be programmed to  their patient specific CSPOT  
(CSP+LV)  configuration  and patients  will  be followed for  6 months. At the  6-month  time  point,  
electrical  characterization  will  be performed via a 12-lead ECG  and clinical  endpoints will  be collected to  
assess the  chronic efficacy  of CSPOT.  
 Subjects  will  be exited  upon  the  completion  of the  6-month  visit. A study  flowchart is  shown   
in Figure  2. 

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  21 of 88  
  
 
 
Figure  2: Study Flowchart  
 
 
 
 
 
 
 
 
6.1 Duration  
 
Study  s
ubjects  will  be followed for  6 months  or until  official  study  closure,  defined  as satisfaction  of 
Medtronic and/or  regulatory  requirements  (per the  Clinical  Investigation  Plan)  and/or  by a decision  by 
[CONTACT_239028], whichever occurs  first.  
 
6.2 Rationale  
The  CSPOT feasibility  study  employs  a prospective,  non -randomized, multi -center, global,  design  
aimed  at optimizing  cardiac resynchronization  pacing.   This  study  is intended to contribute to our  
understanding of optimal  electrical  synchrony  and hemodynamics  from  different pacing  
configurations  in patients who  are  indicated and implanted  with  a CRT -D/CRT -P.   
The  CSPOT study  will  focus  on optimizing pacing while  posing minimal  risk  to the  patient.  
 
 
 
 
 
 
 
 
 
 
Study  Closure  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289937]  been  mitigated to  an acceptable  level.  
6.3 Minimization  of Bias  
Selection  of subjects, treatment of subjects, an d evaluation  of study  data  are  potential  sources of bias.  
 
•  
 
  
 
  
 
  
 
  
 
  
 
 
 
 
  
 
  
 
•  
 
 
 
 
 
7. Product  Description  
 
 
7.1 General  
The  CSPOT Research  System  will  include  both  market  approved  and investigational  components 
that will  allow  collection  of ECG, EGM, LV pressure  and electrical  dyssynchrony metrics  during  
periods  of CRT pacing,  CSP -only  pacing, and CSP+LV  pacing.  
 
Table  4 below  identifies  the  market  approved Medtronic devices that are  compatible with  the  
CSPOT Research  System.  All  CRT -P/CRT -D devices will  be considered investigational  during the  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  23 of 88  
  
course  of the  study. The  CSPOT system  also includes  several  components  that include  both  
market  approved, and investigational  components  identified in  Table  5. 
Instructions for intended use,  maintenance  and calibration  detail  (if applicable),  including  
indications  and contraindications  of the  devices and components  used  in this  study, as  well  as 
medical  procedures  and information  regarding material  in contact [CONTACT_239030], are  
provided in  their respective  manuals.  
 
 
 
Table  4: CSPOT  System  Compatible  Devices  
 
Device  Name  [CONTACT_239109](s)  Market  Released  
 
Percepta  TM  Quad  CRT -P MRI SureScanTM W4TR01 Market  released  
 W4TR04  
(available  in Europe)  Market  released  
 
Serena  TM   Quad  CRT -P MRI  SureScanTM W4TR02 Market  released  
 W4TR05  
(available  in Europe)  Market  released  
Solara  TM   Quad  CRT -P MRI SureScanTM W4TR03 Market  released  
 W4TR06 
(available  in Europe)  Market  released  
 
 
Viva  TM   Quad  S CRT -D DTBB1Q1  Market  released  
 DTBB2Q1  
(available  in Europe)  Market  released  
 
Viva  TM   Quad  XT CRT -D DTBA1Q1  Market  released  
 DTBA2Q1  
(available  in Europe)  Market  released  
 
Brava Quad  XT CRT -D DTBC1Q1  Market  released  
 DTBC2Q1  
(available  in Europe)  Market  released  
Claria  MRITM  Quad  CRT -D DTMA1Q1  Market  released  
 DTMA2Q1  
(available  in Europe)  Market  released  
 
Amplia  MRI  TM  Quad  CRT -D DTMB1Q1 Market  released  
 DTMB2Q1  
(available  in Europe)  Market  released  
 
Cobalt  TM  XT Quad  CRT -D MRI  SureScanTM  
DTPA2Q1  Market  released  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  24 of 88  
  
CobaltTM  HF Quad  CRT -D MRI  SureScanTM DTPB2Q1  Market  released  
CromeTM  HF Quad  CRT -D MRI SureScanTM DTPC2Q1  Market  released  
 
 
 
Table  5: CSPOT  Research  System  Components  
 
 
Model  Number(s)   
Component   
Manufacturer  Investigational  or Market - 
released  
    
EA1B5S,  EA1B5L  (Belt)  
EA1A  (amplifier)  
EA1T (tablet)  ECG Belt  System  Medtronic  Investigational  
825- 0101 Millar  Pressure  Catheter  Millar  Market -Released  
850- 5148 Millar  Connection  Cable  Millar  US:  Investigational  
OUS:  Market -Released  
00EPT01  Cardiotek EP -Tracer  38 System  Cardiotek  Market -Released  
N/A  Threshold  Cable  Any  manufacturer  Market -Released  
5392 Medtronic  External  Pacer  Medtronic  Market -Released  
3830  SelectSecure Medtronic  Pacing  Leads  Medtronic  Investigational  when  used  in the  
study  (due to  implant  location)  
LV Quad  polar  leads:  
 
4298,  4398,  4598  (Attain  
Performa)  
 
4798  (Attain  Stability)  Medtronic  Pacing  Leads  Medtronic  Market -Released  
N/A  RA bipolar  lead  Any  manufacturer  Market -Released  
RV defibrillation  lead  with  
IS1/DF1  connector: 
 
6935  (Sprint  Quattro  single  
coil)  
 
6947  (Sprint  Quattro  dual  
coil)  Medtronic  Defibrillation  Leads Medtronic  Market -Released  
CRT  P Quad  and CRT -D 
Quad  w/DF -1 Connector  
Models  (see Table  4) Medtronic  CRT  devices  Medtronic  Market -Released  
 
7.1.1  Medtronic  Compatible  CRT -D/CRT -P Devices  
Any device  compatible with  the  CSPOT Research  System  (outlined in  Table  4 above) can  be used  in this  
study. CRT -D devices are  indicated for providing cardiac resynchronization  therapy  in heart failure  
subjects  and ventricular  anti -tachycardia pacing  and ventricular  defibrillation  for automated treatment 
of life -threatening ventricular  arrhythmias.   CRT -P devices are  indicated for providing  cardiac  
resynchronization  therapy  in heart failure  subjects. In addition, these  devices can  be used in  subjects  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  25 of 88  
  
with  atrial  tachyarrhythmias,  or those  subjects who  are  at significant risk for developi[INVESTIGATOR_238990].  All devices should  be implanted  as per  the  current  AHA/ACC/HRS  Guideline  [14]. The  
CRT -D/CRT -P devices  used in  the study  are market released  but  are  considered investigational  during  
the  course of the study.  
 
7.1.2  ECG  Belt  System  
 
 
 
 
7.1.3  Millar  Pressure  Catheter  and  Connection  Cable  
The  Millar  pressure  catheter measures  continuously the  LV pressure  and is  market released. The  
connection  cable  for the  catheter transmits  the  LV pressure  data  to the  recording system  and is 
considered investigational  in the  US only  (i.e.  CE-labeled for  EMEA).  
 
7.1.[ADDRESS_289938] configuration  of 12 leads  to understand the  heart’s  electrical  activity.  A 
standard 12 -lead ECG (supplied  by [CONTACT_239031])  is connected to  a Cardiotek  EP recorder  system  will  allow  
measurement of the  necessary  timing  intervals.  
7.1.5  Threshold  Cables  
Threshold cables  are  used  during the  CSPOT  acute protocol.  They  are  used  for the  connecti ons  
between the  Cardiotek  device  and the  leads.  Any market -released single  model  lead  cables  may be 
used  that are  compatible with  the  CSPOT Research  system.   Compatible models can  be found in  the  
CSPOT System  User Manual.    In addition, instead  of a single  cable, two  connected cables (e.g.  Oscor  
ATAR D-R and Oscor  ATAR  D-V2)  that  meet  the  above  may be used.  
7.1.6  Medtronic  External  Pacer  
A Medtronic External  Pulse  Generator  Model  5392 will  be configured to  provide  atrial  pacing and to 
trigger  the  Cardiotek  system. The  external  pacer is a temporary  pacer  that allows  atrial  pacing,  
including control  of the  amplitude  and rate.  
 
7.1.7  Pacing  Leads  
Medtronic compatible (refer to Table  5 above)  commercially  available  transvenous leads  CSP, RV  and 
LV are  required  to be used  in the  study. Any  commercially  available  RA lead  can  be used in  the  study.  
Every subject’s  CRT system  shall  include  the  following leads:  
• Right atrial  pacing lead  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  26 of 88  
  
• Left  ventricular  pacing lead  
• Right ventricular  defibrillation  lead  (CRT -D only)  
• Conduction  system  pacing lead (Model  3830)  
 
1. Right Atrial  Leads  
Any commercially  available  RA lead  
 
2. Left  Ventricular  Leads  
Medtronic commercially  available  LV transvenous pacing leads  are  required . 
 
3. Right Ventricular  Leads  
Medtronic commercially  available  RV pacing  or defibrillation  (for CRT -D) leads  are  required . 
4. Conduction  System  Pacing Leads  
Medtronic commercially  available  CSP pacing  leads  are  required . 
 
7.2 Labeling  
In all geographies, the  CRT -D/CRT -P devices used  in this  study  are  market -released and will  be labeled  
according to  the  approved  CE-mark  labeling.  The  devices  will  be considered investigational  during the  
course  of the  study.  
 
Market -released components  will  be provided with  the  approved  CE-mark  labeling.  
 
In the  US,  investigational  labeling requirements for the  ECG Belt  and Millar  Connector  Cable  will  include  
the  following statements:  
 
“CAUTION  – Investigational  device.  Limited by  [CONTACT_239032]  ([LOCATION_003])  to Investigational  use".  
 
In EMEA,  labeling for  the  ECG Belt  will  include  the  following statement (labeling will  be in English  unless  
otherwise  required for  local  regulations):  
 
“Exclusively  for Clinical  Investigations.”  
 
7.[ADDRESS_289939]  Use  
The  CSPOT system  is compr ised of the  components  identified in  Table  5: CSPOT Research  System  
Components.  The  system  components  have  all been  individually  approved  (with  the  exception  of the  
ECG Belt  and the  Millar  Connection Cable  (US only)) for other  human  use  applications.  The  unique  
aspects  of the  CSPOT system  are  introduced by  [CONTACT_239033].  Each of the  existing elements  have  
instructions  for use  related  to their existing uses;  as part of the CSPOT Research  System,  the  3830  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289940]  of use  in the  intraseptal  location.  
Components  intended for use  in the  sterile  field, including the  leads, pressure  catheter  and lead  
cables/pocket clip are  provided in  sterile  packaging, except  for the  Millar connection  cable.  The  Millar  
connection  cable  may be re-sterilized/sterilized per  its instructions  for use  or a sterile  sleeve  may  be 
used.  Reusable  components that may  be exposed to  body  fluids, including the  ECG Belt  amplifier, the  
ECG cables  and the  lead  cables, can  be cleaned per  their  individual  instructions  for use.  Disposable  
components  of the  system,  including only  the  pressure  sensor catheter  and ECG  electrode  array  have  
a shelf  life of at least  [ADDRESS_289941] Distribution/Accountability  logs  will  be 
used  for tracking of products  during and after the  study. The  tracking method  might vary  but could use  
either an electronic or  paper accountability  logs  provided by  [CONTACT_13735]. The  logs  must  be updated  
when the  investigational  product is  received, opened,  implanted, explanted, disposed  of or  returned  to 
Medtronic. In addition  to tracking the  date of events,  the  log tracks  product information  including, but  
not limited to, date,  model/serial  number/lot number and expi[INVESTIGATOR_238991], subject 
ID of implanted  subject, date  implanted/used, date  explanted  (if applicable), date  returned to  
Medtronic and reason for return  (if applicable),  reason  for and method  of destruction/disposal  for 
explanted  components not returned to  Medtronic (if applicable), and name  [CONTACT_239110]/d isposal  (if applicable).  
 
Medtronic will  perform  periodic reconciliation  of investigational  product to  ensure  traceability.  
 
If there  are  additional  local  requirements related to  the  CSPOT Research  System  beyond what is  
collected by  [CONTACT_239034], this  is the  Investigator’s responsibility  and should  be recorded in  
the  subject’s  medical  records, but will  not be  collected by  [CONTACT_13735]  (e.g., national  registration  card  
number,  identification  code  linked  to names and contact [CONTACT_3031], log of all subjects  enrolled  in the  
study, lot or  batch  number).  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289942]  Return  
All explanted, unused  or malfunctioning devices (devices  or leads  or activators, etc.)  should be  returned  
to Medtronic for analysis when permissible  by [CONTACT_239035]. If the  products are  explanted  
but not returned,  a justification  will  be reported  on the  appropriate  case  report forms  or disposition  
logs. To  receive  a Returned  Product Mailer  Kit, please  contact [CONTACT_239036].  
 
 
8. Study  Site  Requirements  
 
 
8.1 Investigator/Investigation  Site  Selection  
All investigators  managing the  subject’s  health  care  must  be qualified practitioners  and experienced  in 
the  diagnosis  and treatment  of subjects  with  heart failure.  All EP/implanting physicians must  be 
experienced  and/or  trained in  the  handling of CRT -D/CRT -P devices.  
The  role  of the  Principal  Investigator  [INVESTIGATOR_238992] -to-day  conduct of the  clinical  
investigation  as well  as ensure  data  integrity  and the  rights, safety  and well -being  of the  subjects  
involved  in the  clinical  investigation.  
The  principal  investigator [INVESTIGATOR_67417]:  
• Be qualified by  [CONTACT_8640], training, and experience to assume  responsibility  for the  proper  
conduct of the clinical  investigation  
• Disclose  potential  conflicts  of interest,  including financial, that interfere  with  the  conduct of  
the  clinical  investigation  or interpretation  of results  
• Be able  to dem onstrate  that the proposed investigational  study  site:  
 Has  the  required number  of eligible  subjects  needed  within  the  recruitment period  
 Has  one  or more  qualified investigators,  a qualified investigational  study  site  team  
and adequate  facilities  for the  foreseen duration  of the  clinical  investigation  
 
Study  site  personnel  training will  be completed and documented  prior  to participation  in this  study.  
 
 
8.2 Study  Site  Activation  
During the  activation  process (prior  to subject  enrollment), Medtronic will  train  study  site personnel  on 
the  clinical  investigation  plan, on  relevant  standards  and regulations, informed consent, and on  data  
collection  and reporting tools. If new members  join  the  study  site  team,  they  will  receive  training on  the  
applicable  study  requirements  relevant to  their role  before  contributing to  the  study.  
Prior  to performing study  related  activities,  all regulatory  requirements  shall  be fulfilled, including, but  
not limited to the  following:  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  29 of 88  
  
• EC approval  (and voting list,  as required  by [CONTACT_169291])  of the  current version  of the  CIP  and IC 
• Regulatory  Authority  approval  or notification  (as required  per  local  law)  
• Fully  executed  CTA; Medtronic contracts  with participating  institutions/investigators  
through  a Clinical  Tria l Agreement  that defines the  scope  and responsibilities  and  
associated compensation  related  to carrying out the obligations  under a  clinical  study  
sponsored by  [CONTACT_13735]  
• Financial  disclosure  
• CV of investigators  and key  members of the  investigation  study  site  team  (as required). The  
signature  [CONTACT_239111]  3 years prior  to the  date  of activation  of the  study  
site 
• Documentation  of Delegated Tasks  
• Documentation  of Site  Technical  Support  
• Documentation  of study  training 
• Additional  requirements imposed  by [CONTACT_56819], the  EC and RA shall  be followed,  if 
appropriate 
 
In addition,  all participating study  site  staff  must  be trained on  the  current  version  of the  CIP  as well  as 
on the  applicable  study  requirements  depending on  their role  and must  be delegated  by [CONTACT_239037] [INVESTIGATOR_238993].  
Medtronic will  provide  each  study  site  with  documentation  of study  site/investigator  readiness;  this  
letter must be  received  prior  to performing study  related  activities.  
8.3 Role  of the  Sponsor  Representatives  
Sponsor  representatives may provide  support  at the  study  site  as required  for the  study  under  
supervision  of the  Principal  Investigator, including:  
• Provide  st udy  training relevant  and pertinent to  the  involvement  of personnel  conducting  
study  activities  and investigator  responsibilities  
• Technical  support for  acute  study  protocol  and 6 months  follow  up visit under the  
supervision  of a study  investigator, but no data  entry,  shall  be performed  by [CONTACT_239038]  
• Support study  investigators  in performing the  study  implant procedure  
• Monitoring and  auditing  activities  
 
In addition,  for this  study, sponsor  representatives  will  be authorized to  perform  the  following  
significant trial  related  duties:  
• Support data  collection  and performing the  CSPOT protocol  during the  acute and during  
the  6-month  chronic phase  study  follow  up visit.  
• Support data  collection  during the  implant procedure  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289943]/IRB and Medtronic  approval  of this  Clinical  Investigation  Plan, the  informed consent form  
and any  other  applicable  documents must  be obtained prior  to enrolling subjects  in the  study.  
Medtronic will  provide  each  study  site  with  documentation  of study  site/investigator  readiness;  this  
letter must be  received  prior  to subject enrollment. 
When a  patient and the Principal  Investigator  [INVESTIGATOR_166657],  as required, have  personally  
signed  and dated the  informed consent form,  the  patient is considered a subject enrolled in  the  study.  
Subjects  must  provide  informed consent before  any study  related procedures  occur.  The  date  the  
subject signed  the  informed consent form  and data  protection  aut horization  as required  by [CONTACT_239039]’s  medical  records.  
Subjects  will  be screened to  ensure  they  meet all  the  inclusion  and none  of the  exclusion  criteria  prior  
to study  enrollment. 
9.3 Inclusion  Criteria  
• Patient is willing and able  to provide  written  informed consent  
• Subject is  at least  18 years of age  
• Patient is willing and able  to comply  with  the  protocol, including follow -up visits  
• The  patient’s medical  records  must  be accessible  by [CONTACT_239040] -up 
period  
• Standard  CRT- D or CRT -P indications, with  a preference  for IVCD  and non -LBBB  patients,  
where  LBBB is defined  according to  Strauss criteria.  
• De-novo  CRT implant, including upgrade  from  pacemaker or ICD  
 
 
9.4 Exclusion Criteria  
• Subject has  persistent  or permanent AF (Atrial  Fibrillation)/AFL (Atrial  Flutter)  
• Subject has  2nd or 3rd degree  AV (Atrioventricular)  Block  
• Subject has  RBBB  with  no additional  conduction  block  
• Subject has  intrinsic (non -paced)  QRS  width  less than  or equal  to 120 ms  
• Subject experienced MI  within  40 days  prior  to enrollment  
• Subject underwent valve  surgery, within  90 days  prior  to enrollment  
• Subject is  post heart transplantation  or is actively  listed on  the  transplantation  list 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  31 of 88  
  
• Subject is  implanted  with  a LV assist device  
• Subject has  severe renal  disease 
• Subject is  on continuous  or uninterrupted  infusion  (inotropic)  therapy  for heart failure  
• Subject has  severe aortic  stenosis  (with  a valve  area  of <1.0 cm or significant valve  disease  
expected  to be operated within  study  period)  
• Subject has  severe aortic  calcification  or severe  peripheral  arterial  disease  
• Subject has  complex  or repaired  congenital heart disease  
• Subject has  mechanical  heart valve  
• Pregnant or  breastfeeding woman  (pregnancy  test  required for  woman  of child -bearing  
potential  and who  are  not  on a reliable  form  of birth  regulation  method  or abstinence)  
• Subject is  enrolled  in another  study  that could confound the results of this  study  without  
documented  pre -approval  from  Medtronic study  manager  
 
 
10. Study  Procedures  
 
 
10.1 Schedule of Events  and  Data  Collection  
A patient will  be considered enrolled in  the  study  once  they  sign  and date  the  Informed Consent.  
Subjects  will  complete  an in-office  visit at 6 months. The  requirements  for data  collection  and study  
procedures  by [CONTACT_239041]  6 below.  
 
Table  6: Data  collection and study  procedure  requirements  
 
 
 
 
 
STUDY  PROCEDURE  
 
Baseline  
(occur  within  30 
days  prior to 
enrollment)  
 
Implant  
(occur  within  30 
days  after 
enrollment)  
 
6 month follow  
up and  Study  
Exit  
Patient Informed Consent  X   
Inclusion/Exclusion  Assessment  X   
Demographics  X   
Medical History  X   
Physical  Exam  X  X 
Medication  Assessment  X  X 
Baseline  12- Lead ECG  (within  60 days prior  to enrollment/consent)  X   
Baseline  Echocardiography  including LVEF  and  LVESV  (within  60 days prior  
to enrollment/consent)   
X   
NYHA  X  X 
ECG  Belt   X  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  32 of 88  
  
Lead Placement   X  
CSPOT Research  System  Protocol   X  
Insertion  procedure information   X  
Fluoroscopic  Images of final  LBBP  lead placement   X  
Patient Global Assessment    X 
6 Month Echocardiography  including LVEF  and  LVESV  (within 30  days prior  to 
visit)    X 
6 Month 12- Lead ECG  (within  30 days prior  to visit)    X 
Final  device  programming  X X 
Initial  and  Final  Device  Interrogation  (with  either  initial  or final  interrogate  
ALL) and  collect  a .pdd file  X X 
Adverse  Events   
 
 
As they  occur  Hospi[INVESTIGATOR_238994]  
 
10.2 Prior  and Concomitant  Medications/Therapi[INVESTIGATOR_238995]/therapy  restrictions in the  study  unless  they  are  investigational  and may  
confound the  study  results,  in which  case,  prior  approval  would be  needed  from  Medtronic . Medications 
will  be collected at baseline  and at [ADDRESS_289944]’s voluntary  agreement  to 
participate in a particular clinical  study  after information  has  been given to the  subject  on all aspects  of 
the  clinical  study  that are  relevant to  the  subject’s  decision  to participate. This process includes  
obtaining an  ICF  and an Authorization  to Use  and Disclose  Personal  Health  Information/Research  
Authorization/other privacy  language  as required  by [CONTACT_239042]’s  
Institutional  Review  Board/Ethics  Committee  (IRB/EC)  and signed  and dated  by [CONTACT_19578].  
Investigators shall  consider  all subjects  who  meet  eligibility  requirements  for study  participation  to 
avoid any  bias in  the  subject population.   Prior  to enrolling subjects, approval  of the  CIP, ICF, and any  
other  written  study  information  to be provided to the  subjects  must  have  been  obtained from  each  
site’s  IRB/EC.   The  document(s)  must  be controlled (i.e.  versioned  and dated)  to ensure  it is  clear  which  
version(s)  were  approved  by [CONTACT_36985]/EC.   Any adaptation  of the  sample  ICF  must  be reviewed and  
approved  by [CONTACT_239043]/EC reviewing  the  application  prior  to enrolling the  subject.  
The  investigator must  notify  the  subject of any  significant new findings about the study  that become 
available  during the  study  which  are  pertinent to  the  safety  and well -being  of the  subject,  as this  could 
impact a subject’s  willingness to participate  in the  study.  If relevant, approval  may  be requested from  
subjects  to confirm  their continued participation.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289945]  be conducted by  [CONTACT_62674]  [INVESTIGATOR_022]/her  authorized  designee,  and  
the  ICF  and Authorization  to Use  and Disclose  Personal  Health  Information/Research  
Authorization/other privacy  language  as required  by [CONTACT_239044]  a language  
he/she  is able  to read and understand.   The  process  of obtaining informed consent must  be conducted  
without using coercion  or undue  improper influence  on or inducement of the subject to participate by 
[CONTACT_239045].  The  informed consent process  shall  not waive  or appear to  
waive  subject’s  legal  rights.   The  language  used  shall  be as non -technical  as possible  and the  impartial  
witness,  where  applicable.  
The  subject must  have  ample  time  and opportunity  to read and understand the  ICF, to  inquire  about  
details  of the  study, and to  decide  whether  to participate in the  clinical  study.  All questions  about the  
study  should be  answered to  the  satisfac tion  of the  subject.  
When the  subject decides to participate  in the  clinical  study, the  ICF  must  be signed  and personally  
dated by  [CONTACT_239046]. If  applicable, the  witness shall  
also  sign  and personally  date  the  ICF  to attest that the  information  in the  ICF  was  accurately  explained  
and clearly  understood by  [CONTACT_19578], and that informed consent was  freely  given.  
A copy  of the  IC F and the  Authorization  to Use  and Disclose  Personal  Health  Information/Research  
Authorization/other privacy  language, signed  and dated as  required  by [CONTACT_2371], must  be provided to  the  
subject.  
If informed consent is  obtained the same  day  the  subject begins  participating in  study -related  
procedures, it must  be documented in  the subject’s  case  history  that consent was  obtained prior  to 
participation  in any study -related procedures.  
In the  event the  subject cannot read and/or  write,  the  IC process  shall  be obtained through  a supervised  
oral  process .  In this  situation, an independent witness must be  present  throughout  the                   
informed consent process.   The  written  informed consent form  and any  other  information  shall  be read  
aloud and explained  to the  prospective subject.  The  witness  signs  and personally  dates  the  IC attesting  
that the  information  was  accurately  explained and that informed consent was freely  given.  Whenever  
possible, the subject shall  sign  and personally  date  the  informed consent form.  
The  original  of the  signed  IC must  be filed  in the  hospi[INVESTIGATOR_307]/clinical  chart  and/or  with  the  subject’s  study  
documents.  
Detailed documentation  of the  consent process  must  be recorded in  the  subject’s  case  history.  The  
ICF  should document a supervised  oral  process  was  used  for communication  with  the  prospective 
subject and the specific means by [CONTACT_239047].  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  34 of 88  
  
The  ICF  and Authorization  to Use  and Disclose  Personal  Health  information/Research  
Authorization/other privacy  language  as required  by [CONTACT_239048].  
Any Medtronic Field personnel  who  support the CRT -D/CRT -P implant procedure must  be able  to 
review  the  subject’s  original  signed  and dated  ICF  and verify  its completeness  prior  to proceeding with  
the  insertion.  In the  event  the  Medtronic  Field personnel  identify  informed consent as  being  
incomplete,  the study  procedure  will  not be allowed to  occur  until  the  consent of the subject can  be 
adequately  and appropriately  obtained.  
Consistent with  the  DoH, vulnerable  adults  (i.e.  those  subjects  mentally  incapable of giving consent)  
are  excluded  from  this  protocol.   Any subjects  with  mental  incompetence  (e.g., Alzheimer’s, dementia, 
psychiatric disorders, developmental  disorders)  should be  assessed for  vulnerable  status.  If the  IC is 
signed  by [CONTACT_239049], the  monitor  may  discuss  whether the  Investigator 
believes the  subject meets the  definition  of a vulnerable  adult.  This  protocol  defines vulnerable  adult as  
those  subjects  mentally  incapable  of giving consent, in  the  Investigator’s opi[INVESTIGATOR_1649].  The  Investigator  
should consider  the  definition  of vulnerable  adult per  ISO [ZIP_CODE],  which  defines vulnerable  adults  as: 
“individuals  who  are  unable  to fully  understand all  aspects  of the  investigation  that  are  relevant to  the  
decision  to participate, or  who  could be manipulated or unduly  influenced as  a result  of a compromised 
position, expectation  of benefits or fear  of a retaliatory  response.  For  example,  this  could include  
Individuals  with  loss  of autonomy  due  to immaturity  or through  mental  disability, persons in nursing 
homes,  children, impoverished persons, subjects  in emergency  situations, ethnic  minority  groups,  
homeless  persons, nomads, refugees, and those  incapable  of giving IC.  Other vulnerable  subjects  could 
include, for  example,  members of a group  with  a hierarchical  structure  such  as university  students,  
subordinate  hospi[INVESTIGATOR_238996], employees  of the  sponsor, members of the  armed  
forces, and persons kept  in detention.  
10.[ADDRESS_289946]’s  medical  records. A log of  all subjects  enrolled  in the  study  should be  maintained.  Enrollment  
can  be a stand -alone  visit or  can  occur  on the  same  day  as the  baseline  visit. Once  consent is  obtained,  
report adverse  events/deaths, study  deviations  and subject exits as they  occur.  
10.[ADDRESS_289947] enrollment, a baseline  visit will  be performed within  30 days. The  baseline  visit can  be 
a standalone  visit or  occur  on the  same  day  as enrollment.  The  following procedures/data  collection  
will  be conducted during the  baseline  visit:  
• Inclusion/exclusion  criteria  assessment  
• Demographics  
• Medic al History  
• Physical  Exam  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  35 of 88  
  
• Medication  Assessment  
• Baseline  12-Lead ECG  (within  60 days  prior  to enrollment)  
• Baseline  Echocardiography  including LVEF  and LVESV  (within  60 days  prior  to enrollment)  
• NYHA  classification  
• Adverse  events  (as applicable)  
• Hospi[INVESTIGATOR_602] (as applicable)  
• Death  (as applicable)  
• Study  Deviations  (as applicable)  
 
10.6 CRT -D/CRT -P Implant  
Following subject baseline,  implant procedure of the  CRT -D/CRT -P device  will  be performed within  [ADDRESS_289948] enrollment. The  implant  procedure  visit can  be a standalone  visit or  occur  on the  
same  day  as baseline.  The  following procedures/data  collection  will  be conducted during the  implant  
visit:  
• Insertion  procedure  information  
• ECG Belt  application  and data  collection  
• Lead Placement  
• CSPOT Research  System  protocol  
• CSPOT Chronic Final  Device  programming  
• Initial  and Final  Device  Interrogation  (with  either the  initial  or final  being  an interrogate  ALL)  and 
collection  of .pdd file  
• Fluoroscopic Images of final  LBBP lead  placement in RAO  30-45 degrees,  LAO  30-45 degrees,  
and AP  
• Adverse  events (if applicable)  
• Hospi[INVESTIGATOR_602] (if applicable)  
• Death  (if applicable)  
• Device  Deficiency  (if applicable)  
• System  Modifications  (if applicable)  
• Study  Deviations  (if applicable)  
 
10.6.1  CSPOT  Acute Pacing  Protocol  
The  CSPOT Acute Pacing Protocol  and Medtronic CRT -D/CRT -P implant procedure must  occur  within  
30 days  of enrollment  and will  be performed in  accordance  with  the  Medtronic  respective  CRT -D/CRT - 
P implant instructions.  The  CSPOT pacing  protocol  should take  place  prior  to the  implant of the 
Medtronic CRT -D/CRT -P.  During the  CSPOT  pacing protocol,  two  different sets of electrodes  will  be 
placed  on the  patient’s  chest:  1) a  12-lead surface  ECG  and 2) a multi -electrode  ECG- belt.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  36 of 88  
  
Pacing leads  (and defibrillation  lead  for CRT -D) will  then be positioned as  described in  the  CSPOT User  
Manual.  Finally,  a Millar  pressure  catheter  will  be introduced via the  femoral  artery  retrograde  across  
the  aortic  valve  into  the  LV for hemodynamic pressure  monitoring. 
 
The  different pacing configurations  are  depi[INVESTIGATOR_238997]  (LVcs)  pacing (CRT -P 
implants  only), LVcs  and RV  pacing (CRT -D implants  only) , univentricular  CSP (LBBP),  and conduction  
system  pacing optimized therapy  (CSPOT)  which  is dual  LV pacing of best  LVcs  and CSP.  Different  
atrioventricular  (AV)  and intra -ventricular  VV intervals  will  be evaluated. See  figure  3 below  for an 
overview.  
 
Figure  3: Pacing  Configurations  
 
 
 
 
 
 
 
 
 
 

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  37 of 88  
  
•  
  
•  
 
  
 
•  
  
 
 
 
 
•  
 
 
 
  
 
 
 
•  
  
  
 
  
 
•  
  
 
  
 
 
•  
 
 
 
 
 

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289949]  optimization  according  
to ECG Belt  and/or physician discretion . This  includes  the  SAV , PAV, and  VV delay.  The best LVcs 
electrode that was  used  during the acute testing will  also  be used for chronic programming unless 
phrenic nerve stimulation , lead dislodgement  or high capture threshold  occur.   If the  patient is  not  
programmed to  the  CSPOT configuration,  the  subject must  be exited from  the  study.  
 
The  chronic device  programming includes:  
 
Table  7: Device  programming during  chronic  follow  up.  
 
Feature  Programmed  Value  
AdaptivCRT  Nonadaptive  CRT  
V-V pace  delay  According to best  result  from  ECG  Belt  during  
acute  study  and/or physician discretion  
Paced AV  According to best  result  from  ECG  Belt  during  
acute  study  and/or physician discretion  
Sensed  AV Programmed to  a value between ( Paced  AV – 
30ms ) and (Paced AV – 100ms), according to 
physician discretion.  
LV pacing vector  Select  the  best  LV cathode  according to ECG  
Belt  and /or physician discretion.  Select  
anode  according  to physician  discretion.    
Multiple  Point Pacing (MPP)  Off  
RV Pace  Polarity  Bipolar  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289950]  be accompanied by  a deviation.   The  table  below  indicates  the  follow  up visit  
windows.  
 
Table  8: Windows  for follow -up visits  
 
Visit   Window  (days  post  enrollment)   
 Open  Target  Close  
Baseline  0 15 30 
    
Visit   Window  (days  post  enrollment)   
 Open  Target  Close  
Implant  0 15 30 
    
Visit   Window  (days  post  implant)   
 Open  Target  Close  
6-Month  Follow  Up 150  180  210  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289951] chronic data  
from  the  CSPOT system.  
 
The  following information  is required  to be collected at the  6-Month  scheduled follow -up visit:  
• Physical  Exam  
• Medications  Assessment 
• NYHA  Classification  
• Patient Global  Assessment  
• 6-Month  12 lead  ECG (within  30 days  prior  to visit date)  
• 6-Month  Echocardiography  including LVEF  and LVESV  (within  30 days  prior  to visit  date)  
• Final  Device  Programming  
• Initial  and Final  Device  Interrogation  (with  either the  initial  or final  being  an interrogate  ALL)  and 
collection  of .pdd file  
• Adverse  events  (if applicable)  
• Hospi[INVESTIGATOR_602] (if applicable)  
• Device  Deficiencies  (if applicable)  
• Study  Deviations  (if applicable)  
• System  Modifications  (if applicable)  
• Death  (if applicable)  
 
[IP_ADDRESS]  Final  Device  Programming  
After  the  6-month  follow  up visit procedures  are  completed, the subject’s  device  will  be programmed  
per  physician  discretion. A final  device  interrogation  and collection  of .pdd file is required  to capture 
final  device  settings.  
 
10.7.[ADDRESS_289952]’s  exit  will  be 
used  for analysis. Subjects  who  are  exited  from  the  study  prior  to the  [ADDRESS_289953].  
Subjects  are  urged  to remain  in the  study  as long as  possible  but may  be exited  from  the  study  for any 
of the  following situations:  
• Study  completion  or termination  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  41 of 88  
  
• Subject lost to  follow -up 
• CRT -D/CRT -P device  explanted and not replaced  
• Implant  attempt, however,  no CRT -D/CRT -P was  implanted  
• Subject has  an invasive  system  modification  that has  intent to change  the  pacing  
behavior  from  the  acute  system  configuration  settings  
• The  following occurs  during the  lead  positioning in  the  acute  protocol  testing:  
 Unable  to place  the  LBBP  lead  
 Unable  to place  the  LV lead through  the  CS 
 Subject has  a sustained sinus rate  > 110 BPM  
 Subject has  sustained AV  block, AF, or SVT  
• Subject death  
• Subject did not meet  inclusion/exclusion  criteria  
• Subject was  not implanted  with  a Medtronic CRT -D/CRT -D device  
• Subject did not provide  consent or  data  use  protection  authorization  
• Subject chooses  to withdraw  (e.g., consent  withdrawal, relocation  to another  
geographic location)  
• Investigator  deems withdrawal  necessary  (e.g., medically  justified, inclusion/exclusion  
criteria  not met,  failure  of subject to  maintain adequate  study  compliance)  
 
 
The  following information/procedure  is to be collected/performed at study  exit:  
• Date  of Exit  
• Reason  for Exit  
• Initial  and Final  Device  Interrogation  (with  either the  initial  or final  being  an interrogate  
ALL)  and collection  of .pdd file  
• Adverse  Event Collection  
• Device  deficiencies  
• Study  deviations  
If discontinuation  is because  of safety  or lack of effectiveness,  the  subject may  be asked  to be followed 
for collecting safety  data  outside  the  clinical  investigation.  
10.7.[ADDRESS_289954] are  
unsuccessful. The  method  of attempt (e.g., one  letter and one  phone  record, or  two  letters) must  be 
documented  in the  subject’s  medical  record. In addition, regulation  set  forth  by [CONTACT_239050], a person identified by  [CONTACT_239051]  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289955]’s  health status  and a civil  register may  be contact[CONTACT_239052]  [INVESTIGATOR_238998]’s whereabouts  
10.7.[ADDRESS_289956]  Chooses  to Exit (i.e.,  Revokes  Consent)  
A subject can  withdraw from  the  study  at any  time.  If the  subject wishes  to exit  from  the  study  (i.e.  the  
subject revokes consent), the  study  site  is required  to document the reason  for exit  on the  Exit CRF.  In 
addition, study  sites shall  follow  the  regulations  set  forth  by [CONTACT_239053]. Permission  may  be 
requested to  follow  up with  the  subject outside  of the  study  due  to withdrawal  based on problems  
related  to the  investigational  feature  safety  or performance. If possible, the  following data  should be  
collected prior  to subject withdrawal:  
• Reason  for exit  if patient is willing to  share  
• All ongoing AEs  are  resolved  or unresolved  with  no further  actions  planned 
If no physical  visit  is associated  with  the  withdrawal  or withdrawal  occurs  prior  to baseline  visit,  none  
of the  procedures listed  are  required.  
10.7.[ADDRESS_289957] withdrawal  if possible:  
• Reason  for investigator  withdrawal  from  the  study  
• All ongoing AEs  a re resolved  or unresolved  with  no further  actions  planned 
In the  event  of subject  relocation,  it is recommended  to contact [CONTACT_239054].  
10.8 Device Interrogation  
For any  programming changes  or device  interrogations occurring at the  study  site,  an initial  and final  
device  interrogation  .pdd file  (with  either the  initial  or final  being  an “Interrogate  ALL”)  must  be 
obtained and saved  in a digital  format. Store  the  original  file at the  study  site  and send  a copy  to 
Medtronic.   It is recommended  that data  are  not cleared  during any  interrogation.  
10.9 System Modification  
A system  modification  will  be reported  via a System  Modification  CRF in  the  event the  initially  implanted  
device  or leads  require  non -invasive  modification  (repositioning of leads,  device  battery  change  out) 
and the  intent  is to continue  the  same  pacing behavior  as the  original  system  was  configured.  
If the  implanted device  or leads  require  an invasive  modification  (e.g., device  or lead  explant,  device  or 
lead  replacement/repositioning  with  intent  to change pacing  behavior  from  original  system)  the  System  
Modification CRF will be co mp letedand the subject will be ex ited a fter all system and /or procedure related A Es 
have been resolved or remain unresolved w ithno fu rther a ction pla nned. 
In the  event of  a non -invasive  system  modification, the  follow -up schedule  for the  subject will  remain  
unchanged. 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  43 of 88  
  
For any  system  modification  the  following activities  are  required:  
• Complete  the  System  Modification  CRF  regarding details  of the  system  modification  
procedure  
• Device  interrogation  on the  system  modification  if at all  possible:  
 if device  is explanted: Interrogate  ALL and collect .pdd file  
 if new device  implanted: Interrogate  ALL and collect .pdd file  
 if lead  revision: Interrogate  (with  either initial  or final  being  an interrogate  ALL)  and 
collect .pdd file  
• Adverse  Event Collection  if applicable  
• Device  Deficiencies  if applicable  
• Study  Deviations  if applicable  
 
All explanted product sh ould be  returned  to Medtronic for analysis when permissible  by [CONTACT_239055].  
10.[ADDRESS_289958]’s  participation  in the  study, beginning at  
the  time  of informed consent. Additionally, any  device  deficiencies  related to  the  Medtronic  CRT - 
D/CRT -P will  be collected. Adverse  events  and device  deficiencies  will be reported to  Medtronic via  
completion  of eCRFs. See  section  [ADDRESS_289959] data  will  be collected on  electronic case report forms (eCRFs)  via an electronic data  capture 
(EDC) system.  The  investigator  must  ensure  accuracy, completeness and timeliness of the  data  
reported  in the eCRFs. Only authorized persons can  complete and sign  e-CRFs, as  specified  on the  
Delegated  Tasks  List included in  the  Investigator  Site  File.  
Procedures  in the  CIP  require  source  documentation. Source  documentation  is defined  as the  first time  
data  appear, and may  include  original  documents,  data,  and records  (e.g., hospi[INVESTIGATOR_20112], clinical  and 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  44 of 88  
  
office  charts, procedure  reports, laboratory  notes, memoranda, s ubjects’ diaries  or evaluation  
checklists, pharmacy  dispensing  records, recorded data  from  automated instruments, copi[INVESTIGATOR_238999], microfiches, photographic 
negatives,  microfilm  or magnetic media, X -rays, subject files,  device  data  and records  kept  at the 
pharmacy, at the  laboratories and at medico -technical  departments involved  in the  study).  
In general, eCRFs  (or paper copi[INVESTIGATOR_014])  may not serve  as source  documents. Source  documentation  for 
data  elements not routinely  captured in  medical  records may vary  from  study  site  to study  site;  the  
study  site  may use  source  document worksheets  if identified as  source  documents.  
The  investigator must  ensure  the  availability  of source  documents  from  which  the  information  on the  
eCRFs  was  derived. The  type  and location  of source  documents should be  documented. Where  
printouts of electronic medical  records, are provided as  source  documents, or  where  copi[INVESTIGATOR_239000], those  should be  certified. Certification  must  contain  (1) 
the  signature  [CONTACT_239112], (2) the  date  the  copy  was  made  and (3) a  statement  
attesting to  the  accuracy  and completeness of the  copy.  
The  source  documents must  be made  available  for monitoring or  auditing by  [CONTACT_13735]’s  
representative or representatives  of the  competent authorities  and other  applicable  regulatory  
agencies.  
The  CRF may be considered source  for the  following data  collection  elements:  
• Enrollment Notification  
 Study  site  assigned subject reference  
• Baseline  
 Administrative  information  
• AE eCRF  
 Date  study  site  became  aware  of event 
 Relatedness  of  adverse  event  
• DD eCRF  
 Date  study  site  became  aware  of event 
• Subject Death  
 Date  study  site  became  aware  of death  
 Relatedness  of death  
 System  explant  information  
• System  Modification  
 Justification  for explanted  product not being  returned  to Medtronic  
• Deviations  
 Reason  for deviation  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  45 of 88  
  
Device  data  from  transmissions will  be uploaded to  secure  servers.  Media/USB  data  collected  at office  
visits  will  be sent to  Medtronic.   Upon  receipt,  device  data  will  be maintained with  databases  and 
retrieved for  analysis  and reporting.  
Refer to section  16.[ADDRESS_289960] in  an emergency  or in unforeseen  situations 
beyond the  investigator’s  control  (e.g.  subject failure  to attend scheduled  follow -up visits, inadvertent  
loss  of data  due  to computer malfunction, inability  to perform  required  procedures  due  to subject  
illness).  
For  medically  justifiable  conditions  which  preempt a subject’s  ability  to complete a study -required  
procedure, it may  be permitted to  report only  one  deviation  which  will  apply  to all visits  going forward.  
This  may also  apply  for other  unforeseen  situations  (e.g. the  subject permanently  refuses  to complete 
a study  required  procedure  and the  data  will  not  contribute to the  primary  end point analysis).  
However,  prior  ap proval  from  Medtronic  is required  for such  situations.  
All study  deviations  must  be reported on  the  study  deviation  e-CRF regardless  of whether medically  
justifiable, pre -approved  by [CONTACT_13735], an  inadvertent  occurrence, or  taken  to protect the subject in  an 
emergency.  The  deviation  description  and  reason  for deviation  must  be recorded. Multiple deviations  
of the  same  type  at the same  visit may be reported on  one  e-CRF.  
In the  event the  deviation  involves a  failure  to obtain  a subject’s  consent or is made  to protect the life 
or physical  well -being  of a subject in  an emergency,  the  deviation  must  be reported  to the  IRB/EC as  
well  as Medtronic within  five  (5) working days.   Reporting of all  other study  deviations  must  comply  with  
IRB/EC policies and/or  local  laws  and/or  regulatory  agency  requirements  and must  be reported  to 
Medtronic as  soon as possible  upon  the  site  becoming aware  of the  deviation.  Refer to 16.8 for 
geograph y specific deviation  reporting requirements and timeframes for reporting to  Medtronic  
and/or  regulatory  bodies.  
Medtronic is  responsible  for analyzing deviations,  assessing their significance, and identifying  any 
additional  corrective and/or  preventive  actions  (e.g.  amend  the  Clinical  Investigation  Plan, conduct  
additional  training, terminate  the  investigation).   Repetitive or serious  investigator  compliance issues 
may result  in initiation  of a corrective action plan  with  the  investigator  and site,  and in some  cases,  
necessitate  suspending enrollment until  the  problem  is resolved or ultimately  terminating the  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  46 of 88  
  
investigator’s participation  in the  study.   Medtronic will  provide  site -specific reports  to investigators  
summarizing information  on deviations  that  occurred at the  investigational  site  on a periodic basis.  
 
 
11. Risks and  Benefits  
 
 
11.[ADDRESS_289961] -market surveillance.  
The  risk  analysis  process  for the  CSPOT Research  System is being performed  in accordance  with  ISO  
[ZIP_CODE]:[ADDRESS_289962] CRT (CRT -P and/or  CRT -D) implantation. This  is due  to 1) the  
prolonged duration  of the  complete procedure, 2) the  insertion  of the  Millar  catheter  in the  left  
ventricle, and 3) in CRT -D devices,  the  addition  of the  CSP lead  for LBBP.  The  potential  adverse  events  
are  outlined below:  
 
• Allergic reaction  
• AV fistula  
• Bradyarrhythmia  
• Cardiac arrest  
• Cardiac inflammation  
• Cardiac perforation  
• Cardiac tamponade  
• Cardiac valve  damage  
• Discomfort  
• Dizziness  
• Dyspnea  
• Embolism  
• Fever  
• Groin  site  injury  
• Hema toma  
• H
emorrhage  
• Hiccups  
• Hospi[INVESTIGATOR_059]  
• Infection  
• Lethargy  
• Mental  anguish  
• Palpi[INVESTIGATOR_814]  
• Pneumothorax  
• Physical  injury  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  47 of 88  
  
• Return  of cardiac symptoms  
• Skeletal  muscle  sensation  or twitching  
• Skin  disorders  
• SVC tear  
• Syncope  
• Tachyarrhythmia  
• Threshold elevation  
• Tissue  trauma  
• Vessel  perforation  
 
Kidney  dysfunction  could be  another  risk  because  of increased use  of contrast fluid used  during the  
total  study  protocol.  
Bleeding  and bruising may  be more  likely  to occur  with  the  administration  of blood-thinning 
medications (heparin)  to minimize  the  risk  of blood clot formation  during the  procedure.  
Procedure  prolongation  will  not  only  increase  duration  of the  anesthesia  but also  the  risk of infection.  
The  protocol  procedures may take  up to [ADDRESS_289963] CRT procedure time  
which  includes  up to 10 minutes  of fluoroscopy  exposure.  
Placement  of the  3830 lead to  pace  the  left  bundle  branch  could result  in: temporary  or permanent 
right bundle  branch  block, tric uspid valve  damage, or perforation  of the  ventricular  septum.  
 
Additional  potential  risks  associated  with  the  CSPOT Research  System  to a subject participating in  this  
study  are:  
• The  CSPOT system  is investigational  and may be no more  effective  or less  effective  than  a 
commercially  available  CRT system.  
• The  CSPOT system  may recommend values  that are  different than  anticipated due to 
unknown circumstances or medical  conditions.  
• There  may be other  discomforts  and risks  related  to the  CRT -D/CRT -P, Millar  Catheter,  
ECG Belt  and/or  this  study  that  are  not foreseen at this  time.  
• The  lead  im plant configurations  for this  study  are  considered investigational  and have  not  
been studied for  MRI  use.  Therefore, the  MRI  conditional  labeling will  not apply  for these  
patients.  
 
 
11.[ADDRESS_289964]  been  
mitigated; see  Table  9 below. Any potential  risks  associated with  this  study  are  further  minimized by 
[CONTACT_239056].  
In addition,  investigators  will  be actively  involved in  the  implantation  and follow -up of the  subjects  
implanted  with  the  CRT -D/CRT -P device.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289965] prior to, during,  and after  implant of the  
CRT -D/CRT -P device.  Prior  to implant, it  is recommended  subjects  undergo  a complete  physical  
evaluation.  
Medtronic has  further  minimized the  possibility  of risks by [CONTACT_239057] - 
clinical  testing prior to the  CSPOT study, implementing  quality  control  measures into  production  
processes,  providing guidelines for subject  selection  and evaluation, and providing  adequate  
instructions  and labeling.  
After  implantation, subjects  in the  CSPOT  study  will  be followed for  [ADDRESS_289966]  interrogate  the  
CRT -D/CRT -P to  verify  appropriate  function  and to evaluate  pacing and sensing characteristics  and to 
assess any  adverse  events.  
 
Table  9: Potential  risks  and risk  minimization 
 
Potential  risk  Risk  Minimization  
Precursor  to infection  
 
Associated AEs:  Infection,  Cardiac  
inflammation,  Discomfort,  Fever  • CSPOT research  system  design  verification  ensuring  intended 
use in the sterile  field  - including  the leads,  Millar  LV pressure  
catheter,  and lead cables/pocket  clip are all provided  in sterile  
packaging  
• CSPOT research  system  design  verification  ensuring  reusable  
components  can be re-sterilized  – including  IFU instructions  
on re-sterilization  (if applicable)  
• Instruction  provided  in IFU for implant  procedure;  specifically,  
for the placement  of leads,  set- up of Millar  LV pressure  
catheter, and  appropriate  pacing  protocol/configuration  
Precursor  to acute  tissue/vascular  
trauma  
 
Associated AEs:  Cardiac  perforation,  
Cardiac  tamponade,  Cardiac  valve  
damage,  Discomfort,  SVC tear,  
Hematoma,  Embolism,  Hemorrhage,  AV 
fistula,  Cardiac  inflammation,  Tissue  
trauma,  Vessel  perforation  • CSPOT  research  system  design  verification  ensuring  
compliance  to EN [ZIP_CODE]- 1:2006/A1:2013  
• Instruction  provided  in IFU for implant  procedure;  specifically,  
for the placement  of leads  and set-up of Millar  LV pressure  
catheter  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  49 of 88  
  
Potential  risk  Risk  Minimization  
Missing/misleading  information  causing  
insufficient/inappropriate  medical  
intervention  
 
Associated AEs:  Cardiac  arrest,  
Lethargy,  Dizziness,  Return  of cardiac  
symptoms, Syncope,  Threshold  
elevation,  Skeletal  muscle  sensation  or 
twitching,  Discomfort,  Dyspnea,  Mental  
anguish,  Hiccups,  Infection,  
Hospi[INVESTIGATOR_059],  Hematoma  • CSPOT research  system  design  verification  ensuring  
dependability  (instantaneous  reliability  required  for implant)  
and shelf  life 
• Instruction  provided  in IFU to  verify  that components  are not 
used  beyond  prescribed  shelf  life 
Bio-incompatibility  
 
Associated AEs:  Allergic  reaction,  Skin 
disorders  • CSPOT  research  system design  verification  ensuring  no 
bioincompatible  materials  are used  
Arrhythmia  induction  (pacing  during  
vulnerable  period,  proarrhythmic  
pauses,  electrical/mechanical  stimulus)  
 
Associated AEs:  Cardiac  arrest,  
Lethargy,  Dizziness,  Palpi[INVESTIGATOR_814],  
Syncope,  Tachyarrhythmia,  
Bradyarrhythmia  • CSPOT  research  system  design  verification  ensuring  electrical  
immunity  to interference within  its environment  of use 
• Instruction  provided  in IFU for implant  procedure;  specifically,  
for the placement  of leads,  set- up of Millar  LV pressure  
catheter,  and appropriate  pacing  protocol/configuration  
Inadequate  tachyarrhythmia therapy  
 
Associated AEs:  Cardiac  arrest,  
Lethargy,  Dizziness,  Palpi[INVESTIGATOR_814],  Return  
of cardiac  symptoms, Syncope  • CSPOT  research  system  design  verification  ensuring  electrical  
immunity  to interference within  its environment  of use 
Extracardiac  stimulation  
 
Associated AEs:  Dyspnea,  Hiccups,  
Skeletal  muscle  sensation or twitching,  
Discomfort,  Mental  anguish  • CSPOT  research  system  design  verification  ensuring  electrical  
immunity  to interference within  its environment  of use 
• Instruction  provided  in IFU for implant  procedure;  specifically,  
for appropriate  pacing  protocol/configuration  
User/patient  exposure  to physical  injury  
 
Associated AEs:  Cardiac  arrest,  Physical  
injury  • Instruction  provided  in IFU for implant  procedure;  specifically,  
for to include  ways  to secure  components  to minimize  risk to 
the user,  and disclosure  of thermal  risks  and warnings  for the 
isolation  transformer  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289967]  integrity/functionality  failure  
from  environment  influences  
 
Associated AEs:  Many  harm  outcomes  
are possible. Cardiac  arrest  is chosen  as 
the worst -case  outcome  in terms  of 
safety  risk (severity*occurrence).  • CSPOT  research  system  design  verification  ensuring  electrical  
immunity  to interference within  its environment  of use 
 
11.[ADDRESS_289968] personal  benefit  to individual  subjects. The  potential  
benefits of using  the  CSPOT research system  include  receiving a patient specific configuration  to 
optimize pacing.   The  information  gained from  this  study  could result  in the  improved  management  of 
other  optimized pacing therapi[INVESTIGATOR_014].  
 
11.4 Risk- Benefit  Rationale  
The  result of the  analysis  for risks, along with the  mitigation  of the  risks  as described above, led to 
consider  that the potential  benefits that may  derive  from  an optimized and customized  CRT therapy  
outweigh  the  amount of risk. Overall  residual  risk  of participating in  the  CSPOT study  is considered low  
and acceptable.  
 
 
12. Adverse Events  and  Device Deficiencies 
 
 
12.1 Adverse Events  
AE definitions  are  provided in  Table  10. To comply  with  ISO [ZIP_CODE]:2020,  all adverse  events  (AEs)  will  be 
collected throughout the duration  of a subject’s participation  in the  study  and reported per  the  study  
protocol.  In addition, AEs  impacting users or other  persons,  Non -subject Adverse  Events  will  be 
collected. In all geographies, Unavoidable  AEs, listed  in Table  10, need  not be  reported  unless the  
adverse  event  worsens  or is present outside  the  stated timeframe post -implant.  
For  AEs  that require  immediate  reporting initial  reporting may  be done  by [CONTACT_648],  fax, or on the  eCRF  
completing as much information  as possible. The  completed AE  eCRF must  be submitted to  Medtronic  
as soon  as possible. 
Any medication/treatment associated with  the  trea tment of an  AE must  be reported.  
Subject deaths  are  also  required  to be reported. Refer  to Section  12.[ADDRESS_289969] Death collection  and 
reporting requirements.  
12.2 Device Deficiency  
The  DD (Device  Deficiency)  definition  is provided in  Table  10. To comply  with  ISO [ZIP_CODE]:2020,  DD  
information  will  be collected throughout the study  and reported  to Medtronic. Note  that a DD that  
results in an AE to the  subject should be  captured  as an AE only.  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289970]  led to  a SADE  (i.e., if suitable  action  had  not been taken, if  
intervention  had not been made,  or if the  circumstances  had been less  fortunate)  requires  immediate  
reporting.  
12.3 Processing  Updates  and Resolution  
For  any changes  in status  of a previously  reported adverse  event  or DD (i.e., change  in actions  taken,  
change  in outcome, change in relatedness), information  needs to be updated on, or  added to the  
original  AE or DD  form.  All AEs  must  be followed until  the  AE has  been  resolved, is unresolved with  no 
further  actions  planned, the  subject dies or exits the study, or  until  study  closure, whichever occurs  
first.  
In the  event that a subject is  exited  from  the  study  prior  to study  completion, all  efforts  should be  made  
to continue following the  subject until  all AEs  are  resolved  or unresolved with  no further  actions  
planned.  Additionally, if there  are  unresolved system  or procedure  related AEs  at the  time  of study  
completion, all  efforts  should be  made  to collect additional  information  to have  AEs  resolved.  Once  the  
ongoing system  or procedure  AE(s)  is/are  resolved,  the  subject should be  exited.  If AEs  are  still  ongoing  
at study  completion  after  efforts  have  been  made  to resolve  them, it should be  noted  on the  AE CRF  
that the  AE is unresolved  at time of study  exit.  
At the  time  of study  exit, all  collected adverse  events  that are  unresolved must  be reviewed  and an  
update  to the  original  AE must  be reported.  
12.4 Definitions/Classifications  
Adverse  event (AE)  and device  deficiency  (DD)  ISO [ZIP_CODE]:2020 definitions  are  provided in Table  10 
below. Where  the  definition  indicates  “device”,  it refers  to any  device  used in  the  study. This  might be  
the  device  under investigation, or  any market released component of the system.  Where  the  US and 
ISO terminology  differs, the  US term  is listed first, followed by  [CONTACT_239058].  
Table  10:  Adverse  Event  and Device  Deficiency Definitions  
 
General  
Adverse Event  (AE) Untoward  medical  occurrence, unintended disease  or 
injury,  or untoward  clinical  signs  (including  abnormal  
laboratory  findings)  in subjects,  users or other  persons,  
whether  or not  related  to the investigational  medical  
device  and whether  anticipated  or unanticipated.  
NOTE  1: This  definition  includes  events  related  to the  
investigational  medical  device  or the  comparator. 
NOTE  2: This  definition  includes  events  related  to the  
procedures  involved.  
NOTE  3: For  users or other  persons,  this  definition  is 
restricted to events  related  to investigational  medical  
devices  or comparators.  
(ISO [ZIP_CODE]:2020,  3.2)  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289971]  (ADE)  Adverse  event  related  to the  use  of an investigational  
medical  device.  
NOTE  1: This  definition  includes  adverse  events  resulting  
from  insufficient  or inadequate  instructions  for use,  
deployment,  implantation,  installation,  or operation, or 
any  malfunction  of the investigational  medical  device.  
NOTE  2: This  definition  includes  any  event  resulting  from  
an error  use or from  intentional  misuse  of the  
investigational  medical  device.  
NOTE  3: this  includes  ‘comparator’  if the  comparator  is a 
medical  device 
(ISO [ZIP_CODE]:2020,  3.1)  
Device  Deficiency  (DD)  Inadequacy  of a  medical  device  with  respect  to its identity,  
quality,  durability,  reliability,  safety  or performance.  
NOTE  1: Device  deficiencies  include  malfunctions,  use  
errors  and inadequate in the  information  supplied  by [CONTACT_239059].  
NOTE  2: This  definition  includes  device  deficiencies  
related  to the  investigational  medical  device  or the  
comparator. 
(ISO [ZIP_CODE]:2020,  3.19)  
Relatedness  
CRT -D/CRT -P Procedure  Related  An adverse event  that  occurs  that  is directly  related  to the  
insertion  or modification  of the  CRT -P/CRT -D system.  
CRT -D/CRT -P System  Related  An adverse  event  that  occurs  that  is directly  related  to the  
CRT -P/CRT -D system  (including  components  like  the  
CRTP/CRTD  incision/insertion  tools)  
CSPOT  System  Related  An adverse event  that  results  from  the presence  or 
performance of any  component  of the CSPOT  system  
(including  the  Cardiotek,  ECG Belt,  and other  system  
components)  
Cardiovascular  Event  An adverse  event  related  to the  heart  and  blood  vessels  or the  
circulation.  
Not  Related  Relationship  to the device  or procedures  can  be excluded  
when:  
 
• The  event  is not  a known side  effect  of the product  
category  the device  belongs  to or of similar  devices  
and procedures;  
• The event  has no temporal  relationship with  the  use  
of the device  or the  procedures;  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  53 of 88  
  
 • The  serious  event  does  not  follow  a known  response  
pattern  to the  medical  device  (if the  response  pattern  
is previously  known)  and is  biologically  implausible;  
• The  discontinuation  of medical  device  application  or 
the reduction  of the level of activation/exposure  – 
when  clinically  feasible  – and reintroduction  of its use  
(or increase  of the  level of activation/exposure) do 
not  impact  the  serious  event;  
• The  event  involves  a body -site,  or an organ  not  
expected  to be affected  by [CONTACT_239060];  
• The  serious  event  can  be attributed  to another  cause  
(e.g.,  an underlying  or concurrent  illness/clinical  
condition, an effect  of another  device,  drug,  
treatment,  or other  risk factors);  
• The  event  does  not  depend on  a false  result  given  by 
[CONTACT_239061]  (when  applicable);  
• Harm  to the  subject  are not  clearly  due  to use  error;  
In order  to establish  the  non -relatedness,  not  all the  
criteria  listed  above  might  be met  at the  same  time,  
depending  on the type  of device/procedures  and the  
event.  
Possible  The relationship with  the  use  of the  investigational  device  
is weak but  cannot  be ruled  out  completely.  Alternative  
causes are  also  possible  (e.g.  an underlying  or concurrent  
illness/  clinical  condition  or/and  an effect  of another  
device,  drug  or treatment).  Cases were  relatedness  
cannot  be assessed or no information  has  been  obtained  
should  also  be classified as possible.  
Probable  The relationship with  the  use  of the  investigational  device  
seems  relevant  and/or  the  event  cannot  reasonably  be 
explained  by [CONTACT_239062],  but additional  information  
may  be obtained.  
Causal  Relationship  The  event  is associated  with  the  device  or study  
procedures  beyond reasonable  doubt  when:  
 
 The  event  is a known side  effect  of the product  
category  the  device  belongs  to or of similar  
devices  and procedures;  
 The event  has  a temporal  relationship with  
device  use/application  or procedures;  
 The  event  involves  a body -site  or organ  that  
o the investigational  device  or 
procedures  are  applied  to 
o the investigational  device  or 
procedures  have  an effect  on; 
 The  serious  event  follows  a known  response  
pattern  to the  medical  device  (if the  response  
pattern  is previously  known);  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  54 of 88  
  
  The  discontinuation  of medical  device  
application  (or reduction  of the  level of 
activation/exposure) and reintroduction  of its 
use  (or increase  of the  level of  
activation/exposure) impact  on the  serious  
event  (when  clinically feasible);  
 Other  possible  causes  (e.g.,  an underlying  or 
concurrent  illness/clinical  condition  or/and  an 
effect  of another  device,  drug,  or treatment)  
have  been  adequately  ruled out;  
 Harm  to the  subject  is due  to error in use;  
 The  event  depends  on a false  result  given  by [CONTACT_239063]  (when  applicable);  
 
 
To establish  the  relatedness,  not  all the  criteria  listed  
above  might  be met  at the  same  time,  depending  on the  
type  of device/procedures  and the  serious  event.  
Seriousness  
Serious  Adverse  Event  (SAE)  Adverse event  that  led to any  of the following:  
 
a) death,  
b) serious  deterioration  in the health  of the  subject,  users  
or other  persons  as defined by  [CONTACT_239064]:  
1. a life-threatening  illness  or injury,  or 
2. a permanent  impairment  of a  body  structure or a 
body  function,  including  chronic  disease,  or 
3. in-patient  or prolonged hospi[INVESTIGATOR_059],  or 
4. medical  or surgical  intervention  to prevent  life 
threatening  illness  or injury  or permanent  
impairment  to a body  structure or a body  
function, 
c) foetal  distress,  foetal  death  or a congenital abnormality  
or birth  defect  including  physical  or mental  impairment  
NOTE  1: Planned hospi[INVESTIGATOR_113617] a pre -existing  
condition, or a procedure  required  by [CONTACT_10396],  without  
serious  deterioration  in health,  is not  considered  a serious  
adverse  event.  
(ISO [ZIP_CODE]:2020,  3.45)  
Serious  Adverse  Device  Effect  (SADE)  Adverse device  effect  that  has  resulted  in any  of the  
consequences  characteristic  of a  serious  adverse event.  
(ISO [ZIP_CODE]:2020,  3.44)  
Complication  An adverse event  that  includes  the following  is 
considered  a complication:  
• Results  in death,  
• Involves  any  termination  of 
significant  device  function,  or 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  55 of 88  
  
 • Requires  an invasive intervention 
 
Non -invasive  (21 CFR  812):  when  applied  to a 
diagnostic  device  or procedure,  means  one  that  does  
not  by [CONTACT_239065]: 
• Penetrate  or pi[INVESTIGATOR_239001],  the ocular  cavity,  or 
the urethra,  or 
o Penetrate:  to pass,  extend,  pi[INVESTIGATOR_835],  
or diffuse  into or  through  
something;  to enter  by 
[CONTACT_239066];  to gain  
entrance to 
o Pi[INVESTIGATOR_835]:  to force  a way  into or  through  
something  
• Enter  the  ear  beyond the external  auditory  
canal,  the nose  beyond the  nares,  the  mouth  
beyond the  pharynx,  the anal  canal  beyond the  
rectum,  or the  vagina  beyond the  cervical  os 
 
Note  (FDA):  Blood sampling  that involves  simple  
venipuncture  is considered  noninvasive,  and  the use  of 
surplus  samples  of body  fluids  or tissues  that  are  left  over  
from  samples  taken  for non - investigational  purposes  is 
also  considered  noninvasive.  
Observation  Any  Adverse  Event  that  is not  a complication.  
Note  1: Cardiovascular  and Heart  failure  related  AEs  will be 
the only AEs  requiring  classification  of either  Complication  
or Observation  by [CONTACT_239067].  
Unanticipated  Adverse  Device  Effect  (UADE)  Any  serious  adverse  effect  on health  or safety  or any  life- 
threatening  problem  or death  caused by,  or associated  
with,  a device,  if that  effect,  problem,  or death,  was  not  
previously  identified  in a nature,  severity,  or degree  of 
incidence  in the investigational  plan  or application  
(including  a supplementary  plan  or application),  or any  
other  unanticipated  serious  problem  associated  with  a 
device  that  relates  to the  rights,  safety,  or welfare  of 
subjects.  
 
(21 CFR  812.3(s))  
Unanticipated  Serious  Adverse  Device  Effect  ([LOCATION_003]DE):  Serious  adverse  device  effect  which  by [CONTACT_47720],  incidence, severity  or outcome  has  not  
been  identified  in the current  version  of the  risk  
assessment  
 
NOTE  1: Anticipated  serious  adverse  device  effect  
(ASADE) is an effect  which  by [CONTACT_5942],  incidence,  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  56 of 88  
  
 severity  or outcome  has  been  identified  in the risk  
assessment.  
 
(ISO [ZIP_CODE]:2020,  3.42)  
Serious  Health  Threat  Signal from  any  adverse  event  or device  
deficiency  that indicates  an imminent  risk of 
death  or a serious  deterioration  in the health  in 
subjects,  users  or other  persons,  and that  
requires  prompt  remedial  action  for other  
subjects,  users  or other  persons  
NOTE  1: This  would  include  events  that  are  of 
significant and  unexpected  nature  such  that  they  
become  alarming as a potential  serious  health  
hazard  or possibility  of multiple  deaths  occurring  
at short  intervals.  
(ISO [ZIP_CODE]:2020,  3.46)  
Other  
Non -Subject  Adverse  Event  (users or other  persons)  An Adverse Event  or Serious  Health  Threat  related  to the  
investigational  medical  devices  or comparators  that  
impact  users  or other  persons  
Unavoidable  Adverse  Event  An Adverse  Event  inherent  to a surgical  procedure  that  is 
expected  to occur  in all subjects  for a projected  duration  
according  to the Investigator’s  opi[INVESTIGATOR_1649], including,  but not  
limited  to: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unavoidable  adverse  events  are not  reportable  unless  the  AE 
worsens  or is present  outside  the  stated timeframe.   
Event  Description  Timeframe 
(hours) from  
the  Surgical  
Procedure  
Anesthesia  related  nausea  / vomiting  24 
Low -grade  fever  (<100°F or  37.8°C)  48 
Pocket  site  / Incisional  pain  72 
Mild to moderate  bruising  / ecchymosis  168  
Sleep  problems  (insomnia)  72 
Back  pain  related to  laying  on table  72 
Shoulder  pain/discomfort/stiffness  
related to   shoulder  immobilization  
during procedure 72 
 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289972].  
 
 
12.5.1  Adverse Event and  Device Deficiency  Collection  
[IP_ADDRESS]  Adverse  Events  
 
Reporting of AEs  to Medtronic will  occur  on an Adverse  Event eCRF, including a description  of the  
event,  the  diagnosis, the  date  of event  onset, the date  the  site  became  aware  of the  event, the 
relatedness and seriousness of the  event,  diagnostic tests and procedures  performed, actions taken  as 
a result  of the  event,  and outcome  of the  event.  Each AE must  be recorded on  a separate  AE eCRF.  
Subject deaths  are  also  required  to be reported  and should be  collected on  an AE CRF  with  a Fatal  
outcome. Refer to section  12.6.[ADDRESS_289973] implant. In all geographies, unavoidable  adverse  events,  listed in  Table  10, 
need  not be  reported unless  the  adverse  event  worsens  or is present outside the  stated timeframe.  
For  any changes  in status  of a previously  reported AE  (i.e., change  in actions  taken,  change  in outcome,  
change  in relatedness), an  update to the  original  AE must  be provided. All  reported adverse  events  
must  be followed until  the  adverse  event  has  been resolved, the  subject exits the  study  or until  study  
closure, whichever occurs  first.   At the time  of study  exit,  all collected AEs  with  an outcome  of “not  
recovered/not resolved”, “recovering/resolving”  or “unknown” must  be reviewed and updates  
provided as  applicable.  
 
[IP_ADDRESS]  Device  Deficiencies  
Device  deficiency  (DD)  information  will  be collected throughout the study  and reported to  Medtronic.  
Reporting of DDs to Medtronic will  occur  on a device  deficiency  eCRF. Note  that DDs  that result  in an 
adverse  device  effect  (ADE)  to the  subject  should be  captured on  an AE eCRF only. Device  deficiencies  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289974]  (SADE)  (i.e., if suitable  
action  had  not been taken, if intervention  had not been made,  or if the  circumstances  had been less  
fortunate)  require  immediate  reporting.  
12.5.[ADDRESS_289975]  definitions  as outlined in  Table  11. 
Upon  receipt  of AE  at Medtronic,  a Medtronic representative  will  review  the  AE/DD for completeness  
and accuracy  and when necessary  will  request clarification  and/or  additional  information  from  the  
Investigator. Medtronic will  utilize  MedDRA  to assign  a term  for each  AE based on  the  information  
provided by  [CONTACT_11168].  
Regulatory  reporting of AEs  and DDs  will  be completed according to  local  regulatory  requirements.  
Refer to Table  [ADDRESS_289976] regarding  a U(S)ADE,  SAE  and/or  SADE, contact a study  representative 
immediately (refer  to the  study  contact [CONTACT_239068]’s  study  documents  
binder/investigator  site  file or refer to the  Sponsor  contact [CONTACT_239069]).  
An independent  Cl inical  Event Committee  (CEC)  will  conduct a medical  review  and adjudicate  at a 
minimum  all CRT -D/CRT -P system  and procedure -related adverse  events,  all CSPOT system  and 
procedure -related adverse  events,  all cardiovascular  related  AEs  (regardless of seriousness), all SAEs  
and all  AEs  with  a fatal  outcome.  The  CEC will  consist of non -Medtronic employed  physicians  that a re 
not participating investigators  for the  study.  
 
Table  11:  Adverse  Event  Classification  Responsibilities  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  59 of 88  
  
What  is classified?  Who  classifies?  Classification Parameters  
 
 
 
 
 
 
 
 
Relatedness   
Investigator  • CRT -D/CRT -P Procedure  Related  
• CRT -D/CRT -P System  Related  
• CSPOT System  Related  
 
 
Sponsor  • CRT -D/CRT -P Procedure  Related  
• CRT -D/CRT -P System  Related  
• CSPOT System  Related  
• Complication or Observation (for  all system  or procedure  
related  AEs)  
 
 
 
CEC  • CRT -D/CRT -P Procedure  Related  
• CRT -D/CRT -P System  Related  
• CSPOT System  Related  
• Not Related  
• Cardiovascular related  
• Complication or Observation (for  all system  or procedure  
related  AEs)  
 
Seriousness Investigator  SAE,  DD with SADE potential  
Sponsor  SAE,  UADE/[LOCATION_003]DE,  DD with SADE potential  
 
 
Diagnosis  Investigator  Based  on presenting  signs and  symptoms  and  other supporting  
data  
Sponsor  MedDRA  term  assigned  based  on the  data provided by 
[CONTACT_239070],  Non -sudden Cardiac,  Non -Cardiac,  Unknown  
CEC  Sudden  Cardiac,  Non -sudden Cardiac,  Non -Cardiac,  Unknown  
 
 
12.5.3  Adverse  Event and  Device Deficiency  Reporting  Requirements  
Regulatory  reporting of AEs  and DDs  will  be recorded and reported  according to local  regulatory  
requirements. It is the  responsibility  of the  Investigator  and the  sponsor  to abide  by [CONTACT_239071]’s  EC.  
 
Table  12:  Reporting  Requirements  
 
Unanticipated  Adverse Device Effect  (UADE),  Unanticipated  Serious  Adverse Device Effects  ([LOCATION_003]DE)  
Investigator  submit  to: 
Medtronic  Submit  as soon  as possible  as per  local  reporting  requirement,  but  not  later  
than  within  [ADDRESS_289977]  learns  of the  event.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  60 of 88  
  
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
Serious  Adverse Events  (SAE)  in EEA  & [LOCATION_006] 
Investigator  submit  to: 
Medtronic  Submit  as soon  as possible  as per  local  reporting  requirement,  but  not  later  
tha n wi thin 3 calendar days after the  s tudy perso nnel ’s aw areness of the 
event.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
AEs,  Serious Adverse Events  in U.S.  (SAE)/  Adverse Device Effects  (ADE),  SADE,  Deaths 
Investigator  submit  to: 
Medtronic  Submit  as soon  as possible  as per  local  reporting  requirement,  but  not  later  
than  within  [ADDRESS_289978]  learns  of the  event.  
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
Device Deficiency  (DD)/Device Deficiency  with  SADE potential  
Investigator  submit  to: 
Medtronic  Submit  as soon  as possible  as per  local  reporting  requirement,  but  not  later  
than  [ADDRESS_289979]  learns  of the event  or of new  
information  in relation  with  an already  reported  event.  
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  61 of 88  
  
Sponsor  submit  to: 
Regulatory  Authorities  Submit  per  local  reporting  requirement.  
IRB/Ethics  Committee  Submit  per  local  reporting  requirement.  
 
 
12.[ADDRESS_289980]  be reported by  [CONTACT_239072] (AE  with  outcome  
of fatal)  as soon as possible  after  the  investigator  first  learns  of the  death.  
In the  event of a subject’s  death, it is  recommended  that the  implanted system  be explanted and  
returned  to Medtronic for  analysis whenever possible  per  local  process. Local  laws  and procedures  
mus t be followed where  applicable. If any system  component is returned to  Medtronic, internal  return  
product reporting systems may  be used  to gather  additional  information  about the  returned  
device/component.  
A copy  of the  death  certificate, if available  and allowed by  [CONTACT_54443]/local  law, should be  sent to the 
Medtronic clinical  study  team.  When a  death  occurs  in a hospi[INVESTIGATOR_307],  a copy  of the  death  summary report  
and all  relevant  hospi[INVESTIGATOR_20112], if available  should be  sent to the  Medtronic clinical  study  team.  If an 
autopsy  is conducted, a copy  of the  autopsy  report should also  be sent to the  Medtronic  clinical  study  
team  if available  and allowed by  [CONTACT_54443]/local  law. When the  death  occurs  at a remote  study  site,  it is  the  
investigative  study  site’s  responsibility  to attempt retrieval  of information  about the  death.  
Additionally, device  disposition  information should be  updated.  
In summary,  the  following data  will  be collected:  
• Date  of death 
• Detailed description  of death  
• Cause  of death 
• Relatedness to CRT -P/CRT -D system  and/or  procedure 
• Relatedness to CSPOT system  
• Device  interrogation  information/reports and .pdd file  information/reports (if available)  
• Death  summary/hospi[INVESTIGATOR_307]  r ecords  (if available  and allowed by  [CONTACT_54443]/local  law)  
• Autopsy  report (if available  and allowed by  [CONTACT_54443]/local  law)  
• Death  certificate  (if available  and allowed by [CONTACT_54443]/local  law)  
 
12.6.[ADDRESS_289981]’s  death. The  Investigator 
shall  classify  each  subject death  per  the  following definitions:  
• Cardiac  Death: A death  directly  related  to the  electrical  or mechanical  dysfunction of the  heart.  
• Sudden  Cardiac  Death: Natural  death  due  to cardiac causes,  indicated by  [CONTACT_239073];  preexisting heart disease  may 
have  been  known  to be present, but the  time  and mode  of death  are  unexpected. If time  of 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  62 of 88  
  
onset  cannot be determined,  Sudden  Cardiac  Death will  alternatively  be defined as  any 
unexpected  cardiac  death  occurring  out of  the  hospi[INVESTIGATOR_239002].  
• Non -sudden  Cardiac Death: All  cardiac  deaths  that are  not classified  as sudden deaths,  
including all  cardiac deaths  of hospi[INVESTIGATOR_239003].  
• Non -cardiac  Death: A death  not classified  as a cardiac death.  
• Unknown Death  Classification: Unknown  death classification  is intended for use  only  when  
there  is insufficient or  inadequate  information  to classify  the  death.  
 
Table  13:  Subject death  classification responsibilities  
 
What  is classified?  Who classifies?  Classification  Parameters  
Relatedness  Investigator  • CRT -D/CRT -P Procedure  related  
• CRT -D/CRT -P System  related  AEs  
• CSPOT System  related  
• Not related  
• Possibly Related  
• Probably Related  
• Causal Related  
Death  Classification  Investigator  Sudden  Cardiac,  Non -sudden Cardiac,  Non -cardiac,  Unknown 
 
The  CEC will  review  all AEs  with  a fatal  outcome  and provide  a final  adjudication  of both cardiovascular  
event and death  classification.  Regulatory  reporting  of subject deaths  will  be completed according to  
local  regulatory  requirements.  
12.[ADDRESS_289982]  Complaint:  Any  written,  electronic or  oral  communication  that alleges deficiencies  related to  
the  identity, quality, durability, reliability, safety,  effectiveness  or performance  of a medical  device  that  
has  been placed  on the  market.  
It is the  responsibility  of the  investigator  to report all  product complaint(s)  associated  with  a medical  
device  distributed by  [CONTACT_13735], regardless whether  they  are  related to  intended use,  misuse  or abuse  
of the  product. Reporting must  be done  immediately and via the  regular  channels  for market -released  
products. The  reporting of product complaints by [CONTACT_239074].  Medtronic will  notify  the  RAs  (e.g., CA)  as applicable  for the  following  
incidents  immediately  upon  learning of them  and is  not limited to AEs  and DDs only: 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  63 of 88  
  
• Any malfunction  or deterioration  in the  characteristics and/or  performance  of a device,  
as well  as any inadequacy  in the  labeling or  instructions  for use  which  led or might have  
led to the  death  or serious  deterioration  in the  state  of health  of a patient, user,  or other  
person.  
• Any technical  or medical  reason  resulting in  withdrawal  of a device  from  the  market  by 
[CONTACT_239075].  
• Any serious  deterioration  in the  state  of health, including:  
 Life -threatening illness or injury  
 Permanent  impairment  of a body  function  or permanent damage  to a body  
structure 
 A condition  necessitating medical  or surgical  intervention  to prevent  permanent  
impairment  of a body  function  or permanent  damage  to a body  structure 
 
 
13. Data  Review  Committees  
 
 
13.1 Clinical  Events  Committee  
The  study  will  utilize  an Independent Clinical  Events Committee  (CEC)  to adjudicate  a subset  of all  the  
adverse  events collected in  the  study  for an unbiased assessed  of those  related to  the  device  or 
system.  At regular  intervals, an  independent CEC will  conduct a medical  review  at a minimum all CRT - 
D/CRT -P system  and procedure -related adverse  events, all  CSPOT system  related, cardiovascular  
related  AEs, all  SAEs and all  AEs  with  a fatal  outcome  of participants  in the  study.  
The  CEC will  consist of a minimum  of three  (3) non -Medtronic employed  physicians  that  are  not  
participating investigators  for the  study, including  a CEC chairperson. At least  three  CEC  members  
must  adjudicate, at a minimum,  all adverse  events that are  related  to CRT -D/CRT -P system and/or  
procedure,  CSPOT system,  and/or  cardiovascular  related  events . All SAEs, adverse  events  with  
outcome  of death, and cardiovascular  events will  be reviewed  by [CONTACT_239076].   If the  one  physician  
CEC member deems  an event  to be related,  it will  then go to three  CEC member adjudication. The  CEC 
will  operate  under  a charter  that documents  the  process of adjudication of  data  for this study.  
Medtronic per sonnel  may facilitate and participate in an CEC meeting  but will  be non -voting members.  
If the  CEC disagrees  with  the  investigator’s  classification  of the  event,  the  rationale  will  be provided to  
the  investigator. If the  investigator  agrees with  the  CEC’s  adjudication, the CRF  documenting  the  AE 
will  be updated accordingly.  
If the  investigator  does  not  agree  with  the  CEC’s  adjudication  classification, both determi nations  will  be 
provided within  the  final  report; however, the  CEC’s  adjudication  will  be used  for data  analysis. The  
disagreement  will  also  be included in  reporting to  ECs  and regulatory  authorities, if required.  
Source  documents to support adjudication  may be requested.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  64 of 88  
  
14. Statistical  Design  and  Methods  
 
The  CSPOT study  is a prospective,  non -randomized, multi -center, global, feasibility  clinical  study  
designed  to assess different approaches  to resynchronization  in CRT -indicated patients.  
The  study  may enroll  up to 60 subjects  at up to 12 sites in  the  US and Europe,  with  no more  than  15 
subjects  enrolled per  site.   The  site  maximum of 15 subjects  will  ensure  that evidence  generated by  [CONTACT_239077]  a single  site. Study  subjects  will  be followed for  6 months  after  the  
utilization  of the  CSPOT Research  System  and acute  pacing protocol.  
 
 
14.1 General Aspects  of Analysis  
Medtronic statisticians  or designees will  perform  all statistical  analyses.  
The  study  is exploratory  in nature. A separate  Statistical  Analysis  Plan  (SAP)  will  be developed  and 
include  a comprehensive  description  of the  statistical  methods  and analyses to be included in  the  final  
study  report.  Any change  to the  data  analysis  methods  described in  the  protocol  will  require  an 
amendment  only  if it changes  a principal  feature  of the  protocol. Any  other  change  to the  data  analysis  
methods  described in  the  protocol, and the justification  for making  the  change, will  be described in  the  
clinical  study  report.  
Descriptive  statistics  will  be used  to summarize  the  subject demographic and clinical  
characteristics at baseline.  Data  for qualitative  variables  will  be presented  as incidence  
rates  (total  number of subjects, number of events,  and percent). Data for continuous  
variables  will  be summarized usin g measures  of central  tendency and dispersion.  
P-values  for hy pothesis testing will  be evaluated based on  a two -sided  significance  level of 
0.05.  No adjustments will  be made  for multiple  testing because of the  exploratory  
nature  of this  study.  
No imputation  of missing data  is planned, but  missingness will  be summarized as  a binary  variable.  In 
addition, if the  positive  dP/dt max or SDAT  measurements meant to  be observed  during the  CSPOT  
protocol  are  missing for  some  patients, additional  analysis  to characterize  baseline  factors  associated  
with  missing data  may  be considered.  
All subjects  who  signed  the  informed consent document will  be defined as  the  Enrolled  Cohort. The  
Analysis  Cohort is  defined  as subjects  who  are  enrolled , do not violate  any inclusion  or exclusion  
criteria , and have all leads successfully placed during the CSPOT Acute Pacing Protocol. This  may 
include  patients that do not successfully  complete CRT implant or  the  6-month  follow -up visit. The  
Analysis  Cohort will  be used  for the  primary  analysis  approach  for all objectives  unless otherwise  noted. 
Subjects  in the  Enrolled Cohort but not the Analysis  Cohort will not be  included  in the  primary  analyses  
of the  objectives  described here, but will  be reported  in a subject disposition  table,  and may be included 
in some  secondary  analysis  approaches.  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289983]  been  exited.  
14.3 Interim Analysis  
No interim  analyses  are  planned  for this  study.  
14.4 Primary  Objectives  
This  study  has  two  primary  objectives, both based on  data  collected at implant. One compares  
electrical  synchronization  among pacing  configurations  using SDAT, measured  by [CONTACT_239078],  and 
one  compares  hemodynamic response  among configurations  using LV  dP/dt max, measured  by [CONTACT_239079]. Each  objective  entails  two statistical  hypotheses between  pacing configurations:  
CSPOT vs. CSP -only  and CSPOT vs.  Traditional  CRT.  
14.4.1  Primary Objective  #[ADDRESS_289984]  are:  
H0: Improvement  in SDAT relative to baseline in  the  CSPOT pacing configuration  = Improvement in  
SDAT  relative to baseline  in the  CSP -only  configuration   
HA: Improvement in SDAT relative to baseline  in the  CSPOT pacing  configuration  ≠ Improvement in 
SDAT relative to baseline  in the CSP -only  configuration  
The  bipolar  CSP -only  configuration  will  be used  in this  comparison .  
The  null and alternative  hypotheses  for the  second test  are:  
H0: Improvement in  SDAT relative to baseline  in the  CSPOT pacing configuration  = Improvement in 
SDAT relative to baseline  in the  traditional  CRT  configuration  
HA: Improvement in SDAT relative to baseline  in the  CSPOT pacing  configuration  ≠ Improvement in 
SDAT relative to baseline  in the  traditional  CRT  configuration  
For  both  hypothesis tests,  the best LV cathode, chosen for the CSPOT configuration, as described in 
Section 10.6.1, will be used .  
Paired two -sided  t-tests are  planned to test  the  hypotheses, but a Wilcoxon  signed -rank  test  will  be 
considered as  an additional  anal ysis  approach.  
14.4.2  Primary Objective  #[ADDRESS_289985] are:  
H0: Improvement in  positive  LV dP/dt max  relative to baseline in  the  CSPOT  pacing configuration  = 
Improvement in  positive LV dP/dt max  relative to baseline in  the  CSP -only  configuration  
HA: Improvement in  positive LV dP/dt max  relative to baseline in  the  CSPOT  pacing configuration  ≠ 
Improvement in  positive LV dP/dt max  relative to baseline in  the  CSP -only  configuration  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289986]  are:  
H0: Improvement in positive LV dP/dt max relative to baseline in the  CSPOT  pacing configuration  = 
Improvement in positive LV dP/dt max relative to baseline in the  traditional  CRT configuration  
HA: Improvement in positive LV dP/dt max relative to baseline in the CSPO T pacing configuration  ≠ 
Improvement in positive LV dP/dt max relative to baseline in the traditional  CRT configuration  
For  both  hypothesis tests,  the best LV cathode, chosen for the CSPOT configuration, as described in 
Section 10.6.1, will be used .  
Paired two -sided  t-test are  planned to test  the  hypotheses, but a Wilcoxon  signed -rank  test  will  be 
considered as  an additional  analysis  approach.  
For  each  subject and each  pacing configuration, multiple positive LV dP/dt max  measurements  will  be 
taken  because  individual  measurements are known  to be highly  variable. The  primary  analysis  approach  
for this  hypothesis test will  summarize  these  measurements  to one value for  each  subject -pacing  
configuration  combination. However,  a repeated measures analysis  of the  individual  measurements  
may also  be considered as  additional  analysis.  
14.5 Secondary  Objectives  
The  following secondary  objectives  will  all be evaluated, regardless  of their  results  or the  results  of the  
primary  objectives, given the  exploratory  nature  of this  study.  
14.5.1  Secondary  Objective  #1 
 
Descriptive  summary  statistics  of SDAT  improvement relative to baseline (mean,  95% confidence 
interval, median, 25th and 75th percentile, and minimum  and maximum) will  be calculated for  each  
combination  of pacing  configuration, measurement,  and subpopulation.  
Subjects  missing the  data  required  to assign t hem  to a subgroup  for this  objective (i.e.  QRS  width,  
conduction  disorder  presence,  cardiomyopathy  etiology)  will  not be included in  either  subgroup.  
14.5.2  Secondary  Objective  #2 
Descriptive  summary  statistics  of positive LV dP/dt max  improvement relative to baseline (mean,  95% 
confidence interval, median, 25th and 75 th percentile,  and minimum and maximum) will be calculated 
for each  combination  of pacing  configuration, measurement,  and subpopulation.   
Subjects  missing the  data  required  to assign them  to a subgroup  for this  objective (i.e.  QRS  width,  
conduction  disorder  presence,  cardiomyopathy  etiology)  will  not be  included in  either  subgroup.  
14.5.3  Secondary  Objective  #[ADDRESS_289987] with  LVEF measured  at implant and 6 -month  visit, LVEF change  will  be calculated as 
an absolute  change  from  baseline:  
(EF measured  at 6 months)  − (EF measured at  baseline)  
LVEF change  will  then be summarized with  mean,  95%  confidence interval, median, 25th and 75th 
percentile, and minimum  and maximum.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  67 of 88  
  
Subjects  will  be included in  this  analysis  only  if they  are  in the  Analysis  Cohort and successfully  
complete CRT implant and the  6-month  follow -up visit.  
14.5.4  Secondary  Objective  #[ADDRESS_289988] with  LVESV  measured  at implant and 6 -month  visit, LVESV  change  will  be calculated  
as a relative  change  from  baseline:  
 
(LVESV  measured  at 6 months )−(LVESV  measured  at baseline )
LVESVI  measured  at baseline 
 
LVESV change  will  then  be summarized with  mean,  95% confidence interval, median, 25th and 75th 
percentile, and minimum  and maximum.  
Subjects  will  be included in  this  analysis  only  if they  are  in the  Analysis  Cohort and successfully  
complete CRT implant and the  6-month  follow -up visit.  
14.5.5  Secondary  Objective  #5 
The  Clinical  Composite  Score  (CCS)  is a 3- level  categorical  variable  that can take  the  values – 
Improved,  Unchang ed, or  Worsened – at each  follow -up visit. It is based on  mortality,  HF events,  
termination  of device  function, NYHA  score,  and patient global  assessment.  The  count  and proportion  
of subjects  with  each  of these  CCS values based on  the  6-month  visit will  be provided.  
Subjects  will  be included in  this  analysis  only  if they  are  in the  Analysis  Cohort and have an observed 
CCS . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14.8 Sample Size Determination  

This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  68 of 88  
 Because  this  is an exploratory  feasibility  study, sample  size  has  been determined by  [CONTACT_239080], enrollment rates  and timing for  completion.  
 
 
15. Ethics  
 
 
15.1 Statement(s)  of Compliance  
This  study  will  be conducted in  compliance with  international  ethical  and scientific  quality  standards,  
known  as GCP. GCP  includes  review  and approval  by [CONTACT_239081] a study,  
continuing review  of an  ongoing study  by [CONTACT_76467], and obtaining  and documenting  the  freely  given  
informed consent of a subject be fore  initiating  the  study.  
The  CSPOT study  was  designed  to reflect  the  GCP  principles  outlined in  ISO [ZIP_CODE]:[ADDRESS_289989] and credibility  of the   
clinical  investigation  and the  definition  of responsibilities of the  sponsor  and investigators. In  
accordance  with  ISO [ZIP_CODE]:2020, the  sponsor  shall  avoid improper influe nce  on, or  inducement of, the  
subject, monitor, any  investigator(s)  or other parties participating in, or  contributing to, the  clinical  
investigation. All  investigators  shall  avoid improper influence  on or inducement of the  subject, sponsor,  
monitor, other investigator(s)  or other  parties participating in  or contributing  to the  clinical  
investigation. AE  and DD  handling in the  CSPOT study  is ISO [ZIP_CODE]:[ADDRESS_289990]  been implemented through  the  IC process, EC approval, study  training, 
clinical  trial  registration, pre -clinical  testing,  risk -benefit assessment  and publication  policy.  
Ultimately, all study  sites in all geographies  will  follow  and comply  with:  
• Principles  of DoH  
• 21 CFR  Part 11 (Electronic  Records, Electronic Signatures)  
• 21 CFR  Part 54 (Financial  Disclosure  by [CONTACT_168714])  
• The  CTA  
• The  procedures  described within  this  CIP  
• Local  EC Requirements  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  69 of 88  
  
In addition  to the  regulatory  requirements  outlined above, the  study  will  be conducted according to  
federal, national  and local  laws, regulations,  standards,  and requirements of the  countries/geographies  
where  the  study  is being conducted. These  include  but  are  not limited to: 
• In the  [LOCATION_002], the study  will  be conducted under an FDA IDE  in compliance with  
21 CFR  Parts:  
 50: Protection  of Human  Subjects  
 54: Financial  Disclosure  by [CONTACT_168714]  
 56: IRBs  
 812:  IDEs  
• In Europe  the  study  will  be conducted in  compliance with  the  local  regulations  
 
The  study  will  be publicly  registered prior to in accordance  with  the  2007 FDAAA  and DoH  on 
http://clinicaltrials.gov  (PL 110- 85, section 810(a)). In addition, the  study  may be registered in  local  
regulatory  databases  where  required  by [CONTACT_169291].  
Approval  of the  CIP  and CIP  amendments is required  from  the  following groups  prior  to any study  
procedures  at a study  site:  
• Medtronic  
• Principal  Investigators (where  required by  [CONTACT_169291]/regulations)  
• Geography -specific regulatory  authorities  (if regulatory  approval  is required)  
• An independent  medical  EC or  IRB.  
Similarly, approval  of subsequent  revisions  to the  CIP  is required  at each  study  site  from  the  above - 
mentioned groups  prior  to implementation  of the  revised  CIP  at the  study  site.  
 
 
16. Study  Administration  
 
 
16.[ADDRESS_289991] access  to 
the  subjects’ case  histories  (clinic and hospi[INVESTIGATOR_20112], and  other  source  data/documentation)  upon  
request  as per  the  IC, Research  Authorization  (where  applicable)  and CTA.  The  principal  investigator  
[INVESTIGATOR_239004].  
16.1.[ADDRESS_289992] enrollment, study  compliance, number of 
adverse  events,  number  of deviations, observations  from  previous monitoring visits  and any suspected  
inconsistency  in data  that  requires investigation.  Regulatory  documents may  be reviewed at each  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  70 of 88  
  
study  site.  Monitoring for the  study, including, site  initiation  visits, interim  monitoring  visits, and  
closeout visits will  be done  in accordance  to the  study -specific monitoring plan.  
Monitoring visits  may  be conducted periodically  to assess study  site  progress, the  investigator’s  
adherence  to the  CIP, regulatory compliance  including but not limited to EC approval  and review  of the  
study, maintenance  of r ecords  and reports,  and review  of source  documents against subject CRFs in 
accordance  to the  study -specific monitoring plan. Monitors  review  study  site  regulatory  and study  
compliance by [CONTACT_239082] -compliance and communicating those observations  
along with  recommendations  for preventative/corrective actions  to study  site  personnel.  Monitors  
may work  with  study  personnel  to determine  appropriate  corrective action  recommendations and to 
identify  trends  within  the  study  or at a particular  study  site.  
The  Investigator  will  permit  study  related  monitoring,  audits, IRB  review  and regulatory  inspections  by 
[CONTACT_239083].  
Medtronic will  request  that the study  site  upload  identified subject case  history  files and  regulatory  
documents to a secure,  password -protected website  prior  to remote  monitoring visits.  
16.[ADDRESS_289993] party  designated by  
[CONTACT_54452]  a key  coded form.  If it’s impossible  to pseudonymize  (where  the  subject’s  name  [CONTACT_239113],  such  as fluoroscopy  images)  from  the  data  carrier, data  will  not be  transferred  electronically.  
Procedures  in the  CIP  require  source  documentation. Source  documentation  will  be maintained at the  
study  site.  Source  documents, which  may include  worksheets, subject medical  records, programmer 
printouts, and interrogation  files,  must  be created and maintained by  [CONTACT_239084].  
The  investigator will  clearly  mark  clinical  records  to indicate  that the  subject is enrolled in  this  clinical  
investigation.  
The  data  repo rted  on the  CRFs  shall  be derived  from  source  documents and be  consistent with  these  
source  documents, and any  discrepancies shall  be explained in  writing.  See  Section  16.[ADDRESS_289994] -to-disk  data  collected at office visits  will  be sent to 
Medtronic. Upon  receipt,  device  data  will  be maintained with  databases  and retrieved  for analysis  and  
reporting.  
Investigator  will  be required to  sign  off on  all entered  and completed  data on the  eCRF.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -[ADDRESS_289995] Access  to Source Data/Documents  
Medtronic may  conduct  audits  at participating study  sites. The  purpose  of an  audit is  to verify  the  
performance  of the  monitoring process and the  study  conduct, independently  of the  personnel  directly  
involved  in the  study. RAs, such  as the  FDA,  may also  perform  inspections  at participating study  sites. 
The  investigator and/or  institution  shall  permit Medtronic, ECs  and RAs  direct access  to source  data  
and documents  during monitoring, audits  and regulatory  inspections.  
16.[ADDRESS_289996]/SID  relationship  will  be maintained by  [CONTACT_239085].  The  SID  number  is 
to be recorded on  all study  documents  to link  them  to the  subject’s  medical  records at the  study  site.  
Confidentiality  of data  will  be observed  by [CONTACT_239086]. All  data  shall  be secured  against unauthorized access. The  privacy  of each  subject and  
confidentiality  of his/her  information  shall  be preserved in  reports  and when  publishing any  data.  In the  
US, “Protected Health  Information” (PHI) will  be maintained in  compliance with  the  HIPAA of 1996.  To 
maintain  confidentiality, the subject’s  name  [CONTACT_239114]. This  scenario  will  be covered in  the  IC. In the  event  a subject’s  name/PHI  is 
included for  any reason, it will  be blinded as  applicable. In the  event of inability  to blind the  identification  
(e.g., digital  media,  fluoroscopy  images), it  will  be handled in  a confidential  manner by [CONTACT_239087]. Data relating to  the  study  might be  made  available  to third parties  (for  example  in case  of an 
audit performed  by [CONTACT_14687]), provided the  data  are  treated as  confidential  and that the  subject’s privacy  is 
guaranteed. No identifiable  subject informatio n will  be published.  
16.5 Liability/Warranty/Insurance Information  
16.5.[ADDRESS_289997].  
Medtronic maintains  appropriate  clinical  study  liability  insurance  coverage  as required  under applicable  
laws  and regulations  and will  comply  with  applicable  local  law  and custom  concerning specific  insurance  
coverage. If required, a clinical  study  insurance  statement/certificate will  be provided to  the  IRB/EC.  
16.5.2  Insurance  (Europe)  
Medtronic Bakken Research  Site  B.V. is  a wholly  owned subsidiary  of Medtronic, which  as the  parent  
company  of such  entity  maintains  appropriate  clinical  study  liability  insu rance  coverage  as required  
under applicable  laws  and regulations  and will  comply  with  applicable  local  law  and custom  concerning 
specific insurance  coverage. If required, a Clinical  Trial  insurance  statement/certificate will  be provided  
to the  EC.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  72 of 88  
  
16.6 CIP  Amendments  
Any revisions  or amendments to documents that are  submitted to  the  competent  authorities  
(including CIP  and IC) along with  a statement of justification  for the  changes, will  be submitted to  all 
affected RAs  (FDA,  CA)  and governing ECs, according to  applicable  regulations. All  amendments to the  
CIP  shall  be agreed  upon  between  Medtronic and the  principal  investigator(s), or the  coordinating  
investigator. Approval  by [CONTACT_239088]  (where  applicable)  must  be obtained prior  to 
implementing  a CIP  revision  at the study  site.  
16.[ADDRESS_289998]  2 years after  end of study  in 
his/her  region  and after  study  closure  (or longer  if required  by [CONTACT_169291]). Medtronic will  inform  the 
investigator/study  site  when these  documents  are  no longer  required to  be retained.  
No study  document or  image  will  be destroyed without prior  written  agreement between Medtronic  
and the  investigator. The  investigator  should take  measures to prevent accidental  or premature  
destruction  of documents.  Should t he investigator wish to assign  the  study  records  to another  party  or 
move  them  to another  location, advance written  notice  must  be given to Medtronic.  
Medtronic will  retain  the  study  records  according to  Medtronic corporate policy  and record retention  
schedule.  
16.7.1  Investigator  Records  
The  investigator is responsible  for the  preparation  and retention  of the  records  cited below.  All of the  
below  records, with  the  exception  of case  history  records and case  report forms, should be  kept  in the  
Investigator  Site  File  (i.e., the  study  binder  provided to the  investigator)  or Subject Study  Binder. CRFs  
must  be maintained and signed  electronically  within  the  electronic data  capture system  during the  
study. The  following records  are  subject to  inspect ion and must  be retained for  a period of two years  
(or longer  as local  law  or hospi[INVESTIGATOR_239005]) or the  date  that the records are  no longer  
required  for purposes of supporting a pre -market approval  application.  
• All correspondence  b etween  the  EC/IRB, sponsor, monitor, FDA,  RA and  the  
investigator that pertains  to the  investigation, including required  reports.  
• Subject’s  case  history  records, including:  
 Signed and dated IC:  
• U.S.: signed  by [CONTACT_1130].  
• Europe: signed  by [CONTACT_131496].  
 Observations  of AEs/ADEs/DDs  
 Medical  history  
 Baseline, Implant,  CSPOT system  protocol  and follow  up data  (if applicable)  
 Documentation  of the  dates  and rationale  for any deviation  from  the  protocol  
• List of investigation  study  site s 
• FD (if applicable)  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  73 of 88  
  
• Subject screening log & ID log (if applicable)  
• Normal  value(s)/range(s) for clinical  laboratory  test  (if applicable)  
• Lab certificate  (if applicable)  
• Device  Disposition  Logs  (if applicable).  
• Non  implantable  device  Disposition  Logs  (if applicable)  
• All approved  versions of the  CIP, IC,  IBs/Report of Prior  Investigation  Summary  
• Fully  executed  CTA.  
• CV (signed and dated in  Europe  only) of principal  investigators  and key  members of 
investigation  study  site  team  (as required  by [CONTACT_91320]).  
• Documentation  of delegated  tasks.  
• EC approval  documentation.  Written  information  that the  investigator  or other  study  
staff, when member of the  EC, did not participate  in the  approval  process. Approval  
documentation  must  include  the  ECs  composition, where  required  per  local  law.  
• RA notification, correspondence and approval, where  required  per  local  law.  
• Study  training records  for study  site  staff.  
• Insurance  certificates  (Europe  only).  
• Any other  records  that FDA and local  regulatory  agencies  require  to be maintained.  
• Final  Study  Report including the statistical  analysis.  
 
16.7.2  Sponsor  Records  
Medtronic shall  maintain  the  following accurate, complete,  and current records:  
• All correspondence  which  pertains  to the  investigation  
• Investigational  device  traceability  record containing  Model  and serial  numbers of 
devices,  shippi[INVESTIGATOR_239006],  
location  (if different than  person shipped  to),  transfer and receipt  by [CONTACT_231011]  (if 
applicable)  
• Non  implantable  d evice  traceability  records containing Model  and serial/lot numbers,  
shippi[INVESTIGATOR_239006],  location  (if 
different than  person shipped to), transfer and receipt by [CONTACT_231011] (if applicable)  
• Sample  of label  attached to  investigational  device  
• Signed Investigator  Trial  Agreements,  FD (if applicable)  and current signed  and dated 
(Europe  only)  CV of principa l investigator and key  members of the  investigation  study  
site  team  (as required  by [CONTACT_169291])  
• All approved  IC templates, and other  information  provided to  the  subjects  and 
advertisements,  including translations  
• Copi[INVESTIGATOR_239007]/roster/letter  of assurance  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  74 of 88  
  
• Names of the  institutions  in which  the  study  will  be conducted  
• RA correspondence, notification  and approval  as required  by [CONTACT_54458]  
• Insurance  certificates  (Europe  only)  
• Names/contact [CONTACT_239089]  
• Monitoring visit reports  
• Statistical  analyses  and underlying supporting data  
• Final  report of the study  
• The  CIP, IB/Report of Prior  Investigations  summary  and study  related  reports, and  
revision s 
• Study  training records  for study  site  personnel and Medtronic personnel  involved in  the  
study  
• Any other  records  that local  regulatory  agencies require  to be maintained. 
 
Medtronic records  and reports  will  be maintained in  a password -protected document management  
system,  and paper documents  (where  applicable)  will  be stored in  stored in  secured file  cabinets at 
Medtronic during the  course  of this  study.  
After  closure  of the  study  Medtronic will  archive  records  and reports  indefinitely.  
16.8 Reporting  Requirements  
16.8.1  Investigator  Reports  
The  investigator is responsible  for the  preparation  (review  and signature)  and submission  to the  
sponsor of all  case  report forms, adverse  events  and adverse  device  effects  (reported per the  country - 
specific collection  requirements),  device  deficiencies, deaths, and any  deviations  from  the  clinical  
investigation  plan.  If any action  is taken  by [CONTACT_239090], copi[INVESTIGATOR_239008]  a timely  manner. Reports  are  subject to  inspection  
and to  the  retention  requirements as described above  for investigator  records.  
Safety  data  investigator reporting requirements are  listed  in Section  12.5.3.  The  investigator  shall  
prepare and submit in  a complete,  accurate  and timely  manner the  reports  listed  in this  section.  
 
Table  14:  Investigator  reports  applicable  for all geographies  per  Medtronic  requirements  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  75 of 88  
  
Report  Submit to  Description/Constraints  
Withdrawal  of IRB/EC 
approval  Sponsor  and 
Relevant  
Authorities  The  investigator must  report a withdrawal  of approval  by [CONTACT_239091]/EC of the  investigator’s  part  of the  
investigation  within  5 working days.  
 
 
 
 
Study  Deviations   
 
 
Sponsor  and 
IRB/EC  Any deviation  from  the  clinical  investigational  plan  shall  be 
recorded together with  the  explanation  of the  deviation.  
Notice  of deviations  from  the  CIP  to protect  the  life or 
physical  well -being of a subject in  an emergency  shall  be 
given as soon  as possible, but no later  than  5 working days  
after  the  emergency  occurred.   Except in such  emergency,  
prior  approval  is required  for changes  in the  plan  or 
deviations.  
 
Final  Report  IRBs/ECs  and 
Relevant  
Authorities  This  report must  be submitted within  3 months  of study  
completion  or termination.  
 
  
 
   
 
   
 
   
 
 
Table  15:  Additional  Investigator  reports  applicable  to the  [LOCATION_002]  per  FDA regulations  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  76 of 88  
  
Report  Submit to  Description/Constraints  
Withdrawal  of IRB/EC 
approval  (either  
suspension or 
termination)   
 
Sponsor  The  investigator must  report a withdrawal  of approval  by [CONTACT_239091]/EC of the  investigator’s  part  of the  
investigation  within  5 working days.  (21 CFR  812.150(a)(2))  
 
Progress report  Sponsor  and 
IRB/EC  The  investigator must  submit this  report to  the  sponsor and  
IRB/EC at regular  intervals, but in  no event less  than  yearly 
intervals. (21 CFR  812.150  (a)(3)).  
 
 
 
 
 
 
Study  deviations   
 
 
 
 
Sponsor  and 
IRB/EC  Notice  of deviations  from  the  CIP  to protect  the  life or 
physical  wellbeing of a subject in  an emergency  shall  be 
given as soon  as possible, but no later  than  [ADDRESS_289999]  be approved by  [CONTACT_13735], the 
IRB/EC,  and the  FDA/applicable  RA.   If the  deviation  does  not  
affect these  issues then  only  Medtronic  must  approve  it. (21  
CFR  812.150(a)(4))  
Failure  to obtain  IC 
prior  to 
investigational  device  
use   
Sponsor  and 
IRBs/ECs  If an investigator  uses a  device  without obtaining IC,  the  
investigator shall  report such  use  within  5 working days  after  
device  use.  (21 CFR  812.150(a)(5))  
 
 
Final  report  Sponsor  
IRBs/ECs  
Relevant  
Authorities  This  report must  be submitted within  3 months  of study  
completion  or termination  of the  investigation  or 
completion  or termination  of the  investigator’s  part of the 
investigation.  (21 CFR  812.150(a)(6))  
 
 
Other   
 
IRB/EC and FDA  An investigator  shall, upon  request  by a reviewing IRB/EC,  
FDA or  any other  RA, provide  accurate, complete,  and  
current information  about any  aspect  of the  investigation.  
(21 CFR  812.150(a)(7))  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  77 of 88  
  
Table  16:  Investigator  reports  applicable  to Europe  per  ISO  [ZIP_CODE]  
 
Report  Submit to  Description/Constraints  
Withdrawal  of IRB/EC 
approval  Sponsor  Report if required  by [CONTACT_169291].  
Progress Report  Sponsor  and 
IRB/EC  Provide  if required  by [CONTACT_239092]/EC.  
 
 
 
Study  Deviations   
Sponsor,  
Competent  
Authority  and 
IRB/EC  Any deviation  from  the  CIP  shall  be recorded together with  
an explanation  for the  deviation.   Deviations  shall  be 
reported  to the  sponsor  who  is responsible  for analyzing  
them  and assessing their significance.  
Note: When relevant, ethics  committees,  CAs  or the 
appropriate  RAs  should be  informed. (ISO [ZIP_CODE]:2020)  
 
Failure  to obtain  IC Sponsor  and 
IRBs/ECs  IC shall  be obtained in  writing and documented  before  a 
subject is  enrolled  into  the  clinical  investigation.   (ISO  
[ZIP_CODE]:2020)  
 
16.8.2  Sponsor  Reports  
Medtronic shall  prepare  and submit the following complete,  accurate, and timely  reports  listed  in the  
tables  below  (by [CONTACT_13736]).  In addition  to the  reports  listed  below, Medtronic shall, upon  request  of 
the  reviewing EC, RA or  FDA, provide  accurate, complete and current information  about  any  aspect of 
the  investigation. Safety  data  Medtronic reporting requirements are  listed  in section  12.5.3.  
Table  21:  Sponsor  reports  for Europe  
 
Report  Submit to  Description/Constraints  
 
Premature  
termination  or 
suspension of the  
clinical  investigation  Investigators,  
IRB/EC,  
Relevant  
authorities  and 
Head  of the  
Institution   
 
Provide  prompt notification  of termination  or suspension  
and reason(s). (ISO [ZIP_CODE]:2020)  
 
 
Withdrawal  of IRB/EC 
approval  Investigators,  
Head  of 
Institution,  
IRB/EC and 
relevant  
authorities   
 
Investigators, IRBs/ECs will  be notified only  if required  by 
[CONTACT_239093]/EC.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  78 of 88  
  
Report  Submit to  Description/Constraints  
 
 
Withdrawal  of CA  
approval  Investigators,  
Head  of 
Institution,  
IRB/EC,  and  
relevant  
authorities   
 
Investigators, IRBs/ECs will  be notified only  if required  by 
[CONTACT_239093]/EC.  
Progress Reports  IRB/EC and 
RAs  This  will  be submitted to  the  IRB/EC only  if required  by [CONTACT_91161]//EC).  
 
 
 
 
Final  report   
 
 
Investigators,  
IRB/EC,  and  
RAs  if required  For  studies  with  study  sites complying to  ISO  [ZIP_CODE]:  
• The  investigator shall  have  the  opportunity  to review  
and comment  on the  final  report.  
• If a clinical  investigator  does not agree  with  the  final  
report, his/her comments shall  be communicated to  
the  other  investigator(s).  
• The  coordinating investigator  [INVESTIGATOR_239009]. If 
no coordinating investigator  [INVESTIGATOR_54396], then  the  
signature  [CONTACT_239115] [INVESTIGATOR_239010].    (ISO [ZIP_CODE]:2020)  
 
 
 
Study  deviation   
 
 
Investigators  Ensure  that all  deviations  from  the  CIP  are  reviewed  with  the  
appropriate  clinical  investigator(s),  are  reported on  the  CRFs  
and the  final  report of the clinical  investigation.   (ISO  
[ZIP_CODE]:2020)  
Study  site  specific study  deviations  will  be submitted to  
investigators periodically.  
 
16.[ADDRESS_290000] Operating Procedures and as  
indicated in  the  CTA.  
16.9.1  Publication  Committee  
Medtronic may  form  the  CSPOT Publication  Committee  from  study  investigators.  Medtronic  
personnel may serve  as me mbers of the  committee.   This  committee  will  manage  study  publications 
with  the  goal  of publishing findings  from  the  data.   The  Publication  Committee  will  develop  the  final  
Publication  Plan as a separate  document.  
The  Publication  Committee’s  role  is to: 1) manage  elements addressed in  the  publication  plan  as 
outlined in  this  appendix, 2) develop  the  final  Publication  Plan  under separate  cover, 3) execute  the  
Publication  Plan,  4) oversee  the  publication  of primary, secondary  and ancillary  study  results,  5) review  
and prioritize  publication  proposals, 6) provide  input  on publication  content, and 7) determine  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  79 of 88  
  
authorship.  In addition, the  committee  will  apply  and reinforce  the  authorship  guidelines  set  forth  in 
the  Publication  Plan. 
Membership  in the  Publication  Committee  does  not guarantee  authorship.   The  committee  will  meet at  
as needed.  
16.9.2  Management of Primary,  Secondary,  and  Ancillary  Publications  
The  Publication  Committee  reviews,  prioritizes, and manages  all pub lications  including  primary,  
secondary  and ancillary  publications.   Primary  and secondary  publications  are  those  that address  
analyses  of any  or all primary  objectives  or secondary  objectives, respectively,  as specified in  the  CIP.  
An ancillary  publication  is any  publication  that  does  not  address the  study  objectives  identified in  the  
CIP.   They  include  publications  proposed and developed  by [CONTACT_239094],  
clinicians  participating in  this  study, and clinicians  not participating  in this  study.   The  committee  will  
work  with  Medtronic to  ensure  that requests  do not present  conflicts  with  other  proposals, are  not  
duplicative, and to  determine which  ancillary  publication  proposals, if  any, will  be supported.  
The  committee  may decide  that no publications, including abstracts, will  be published  prior  to the  end 
of the  study  or with  individual  study  site  data.   Requests for publications on study  objectives utilizing  
subset  data  (e.g., regional)  will  be evaluated for  scientific validity  and the  ability  of Medtronic to provide  
resources.  
16.9.3  Criteria for Determining  Authorship  
Publications  will  adhere  to authorship  criteria  defined  by [CONTACT_239095]  (ICMJE, Uniform  requirements  for manuscripts  submitted to  biomedical  journals,  
www.icmje.org).  Individual  authorship  criteria  defined  by [CONTACT_239096].  
Authors, including Medtronic personnel,  mu s t at a minimum  meet  all of the  conditions  below:  
• Substantial  contributions  to conception  and design  of the  work, or  the  acquisition,  
analysis, or  interpretation  of data  for the  work; AND  
• Drafting the work  or revis ing it critically  for important intellectual  content; AND  
• Final  approval  of the  version  to be published; AND  
• Agreement  to be accountable  for all aspects of the  work  in ensuring that questions 
related  to the  accuracy  or integrity  of any  part of the  work  are  appropriately  
investigated and resolved.  
Decisions  regarding authorship  and contributor -ship  will  be made  by [CONTACT_239097]. The  selected  
authors  will  be responsible  for drafting the publication. All  selected  authors  must  fulfill  the  authorship  
conditions  stated above  to be listed  as authors, and all  contributors  who  fulfill the  conditions  must  be 
listed  as authors.  
All investigators  not listed  as co-authors  will be acknowledged as  the  “Medtronic CSPOT Study  
Investigators”  and will  be individually  listed  according to  the  guidelines of the  applicable  scientific  
journal  when possible  and affiliation. Any  other contributors  will  be acknowledged by  [CONTACT_239098].  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -2022  Page  80 of 88  
  
  
 
16.9.4  Transparency  
Transparency  of clinical  study  results will  be maintained by  [CONTACT_239099]:  
• A final  report, describing the  results of all  objectives  and analysis, will  be distributed to  
all investigators, ECs  and CAs  of participating  countries  when required by  [CONTACT_169291]  
• Registering and posting the  study  results on a <publicly  accessible  database, e.g., 
ClinicalTrials.gov>  based on  the  posting rules stipulated  
• Submitting for  publication  the  primary  study  results after  the  study  ends  
• Disclosing conflicts of interest  (e.g., financial)  of the  co-authors  of publications  
according to  the  policies set  forth  by [CONTACT_239100]  
• Making an  individual  study  sites study  data  accessible  to the  corresponding investigator  
after  the  completion  of the  study, if requested  
16.10  Suspension  or Early Termination  
16.10.1  Planned Study  Closure  
Study  Closure  is a process  initiated by  [CONTACT_239101] a study  closure  letter.  Study  closure  is defined  as 
closure  of a study  that occurs  when Medtronic and/or  regulatory  requirements have  been  satisfied per  
the  CIP  and/or  by a decision by [CONTACT_239102]), whichever occurs  first. The  study  closure  process is 
complete upon  distribution  of the  Final  Report or  after final  payments,  whic hever occurs  last. Ongoing  
EC/IRB oversight is  required  until  the  overall  study  closure  process  is complete. Upon  study  closure,  
subjects  should be  managed and followed per  physician  discretion.  
16.10.[ADDRESS_290001]. This is possible  for the  whole  study  or a 
single  study  site.  
[IP_ADDRESS] Study -wide termination  or suspension 
Possible  reasons for considering study -wide  suspension  or termination  of the  study  include  but are  not  
limited  to: 
• AEs  associated with  the  system  or product under investigation  which  might endanger 
the  safety  or welfare  of the  subject  
• Observed/suspected performance  different from  the  product’s  design  intent  
• Decision  by [CONTACT_239103] (where  the  study  is operating under RA)  
• Technical  issues during the  manufacturing process 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -202 2 Page  81 of 88  
  
[IP_ADDRESS] Investigator/study  site termination  or suspension 
Possible  reasons for investigator  or study  site  termination  or suspension include  but are  not limited  to: 
• Failure  to obtain  initial  EC approval  or annual renewal  of the  study  
• Persistent  non -compliance to the  clinical  investigation  (e.g.  failure  to adhere  to 
inclusion/exclusion  criteria, failure  to follow  subjects  per  scheduled follow -ups)  
• Lack  of enrollment  
• Noncompliance  to regulations  and the  terms of the  CTA (e.g.  failure  to submit data  in a 
timely  manner, failure  to follow -up on data  queries and monitoring observations  in a 
timely  manner, etc.)  
• EC suspension of the  study  site 
• Fraud or  fraudulent  misconduct is  discovered  (as defined  by [CONTACT_239104])  
• Investigator  request (e.g. no longer  able  to support the study)  
 
16.10.3  Procedures for Termination  or Suspension  
[IP_ADDRESS] Medtronic -initiated  and  regulatory  authority -initiated  
• Medtronic will  promptly  inform  the  clinical  investigators  of the  termination  or 
suspension and the  reasons and inform  the  RAs  where  required  
• In the  case  of study  termination  or suspension  for reasons other  than  a temporary  EC 
approval  lapse,  the  investigator  will  promptly  inform  the  EC 
• In the  case  of study  termination, the investigator  must  inform  the  subjects  and may  
inform  the  personal  physician  of the  subjects  to ensure  appropriate  care  and follow -up 
is provided 
• In the c ase  of a study  suspension, subject enrollment must  stop  until  the  suspension  is 
lifted by  [CONTACT_13735]  
• In the  case  of a study  suspension, enrolled  subjects  should continue  to be followed out  
of consideration  of their safety, rights  and welfare  
[IP_ADDRESS] Investigator -initiated  
• The  investigator will  inform  Medtronic and  provide  a detailed written  explanation  of the  
termination  or suspension  
• The  investigator will  promptly  inform  the  institution  (where  required per  regulatory  
requirements)  
• The  investigator will  promptly  inform  the  EC 
• The  investigator will  promptly  inform  the  regulatory  authorities  
• The  investigator will  promptly  inform  the  subjects  and/or  the  personal  physician  of the  
subjects  to ensure  appropriate  care  and follow -up is provided 
• In the  case  of a study  suspension, subjects enrolled  should continue  to be followed out  
of consideration  of their safety, rights  and welfare  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -202 2 Page  82 of 88  
  
[IP_ADDRESS] Ethics Committee -initiated  
• The  investigator will  inform  Medtronic and  provide  a detailed written  explanation  of the  
termination  or suspension within  5 business days  
• Subject enrollment must  stop  until  the  suspension  is lifted  
• Subjects  already  enrolled  should continue  to be followed in  accordance with  EC policy  or 
its determination  that  an overriding safety  concern  or ethical  issue  is involved  
• The  investigator will  inform  his/her  institution  (where  required per  local  requirements)  
• The  investigator will  promptly  inform  the  subjects, and/or  the  personal  physician  of the  
subjects, with  the  rationale  for the  study  termination  or suspension  
 
 
17. References  
 
 
1. Packer,  M., Proposal  for a new  clinical  end point to  evaluate the efficacy  of drugs  and devices  in the 
treatment of chronic  heart  failure.  J Card  Fail, 2001.  7(2): p. 176- 82. 
2. Packer,  M., Development and Evolution of  a Hierarchical  Clinical Composite  End Point  for the 
Evaluation of Drugs  and Devices  for Acute  and Chronic  Heart  Failure:  A 20-Year  Perspective.  
Circulation,  2016.  134(21):  p. 1664- 1678.  
3. Lustgarten,  D.L.,  et al., His-bundle  pacing versus  biventricular  pacing  in cardiac  resynchronization 
therapy  patients:  A crossover  design  comparison. Heart  Rhythm,  2015.  12(7):  p. 1548- 57. 
4. Ajijola,  O.A.,  et al., Permanent  His-bundle  pacing  for cardiac  resynchronization therapy:  Initial  
feasibility  study  in lieu of left ventricular  lead.  Heart  Rhythm,  2017.  14(9): p. 1353- 1361.  
5. Arnold,  A. D., et al., His Resynchronization Versus  Biventricular  Pacing in Patients  With  Heart  Failure  
and Left Bundle  Branch Block.  J Am Coll Cardiol,  2018.  72(24): p. 3112- 3122.  
6. Upadhyay,  G.A.,  et al., On-treatment  comparison  between  corrective  His bundle  pacing  and 
biventricular  pacing  for cardiac  resynchronization:  A secondary  analysis  of the His-SYNC  Pi[INVESTIGATOR_239011].  
Heart  Rhythm,  2019.  16(12): p. 1797- 1807.  
7. Vijayaraman, P.,  et al., His-Optimized  Cardiac Resynchronization Therapy  to Maximize  Electrical  
Resynchronization:  A Feasibility  Study.  Circ Arrhythm  Electrophysiol,  2019.  12(2):  p. e006934.  
8. Boczar,  K., et al., Cardiac  resynchronization therapy  with His  bundle  pacing.  Pacing  Clin 
Electrophysiol,  2019.  42(3):  p. 374- 380.  
9. Deshmukh,  A., et al., Sequential  His bundle and  left ventricular  pacing  for cardiac  resynchronization. J 
Cardiovasc  Electrophysiol,  2020.  31(9):  p. 2448- 2454.  
10. Huang,  W., et al., A Novel  Pacing Strategy  With  Low and Stable  Output:  Pacing the Left Bundle  
Branch  Immediately  Beyond  the Conduction Block.  Can J Cardiol,  2017.  33(12):  p. 1736 e1-1736 e3. 
11. Zhang,  W., et al., Cardiac resynchronization  therapy  by [CONTACT_239105].  Heart  Rhythm,  2019.  16(12):  p. 1783- 1790.  
12. Li, X., et al., Left bundle  branch area pacing delivery  of cardiac  resynchronization  therapy  and 
comparison  with  biventricular pacing.  ESC Heart  Fail, 2020.  7(4): p. 1711- 1722.  
13. Wang,  Y., e t al.,  The efficacy  of left bundle  branch  area  pacing compared  with  biventricular  pacing  in 
patients  with heart  failure:  A matched case -control  study.  J Cardiovasc  Electrophysiol,  2020.  31(8):  p. 
2068- 2077.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -202 2 Page  83 of 88  
  
14. Epstein,  A.E.,  et al., ACC/AHA/HRS  2008 Guidelines  for device -based  therapy  of cardiac  rhythm  
abnormalities.  Heart  Rhythm,  2008.  5(6): p. e1-62. 
15. Sterlinski,  M., et al., In Heart  Failure  Patients  with  Left Bundle  Branch Block  Single  Lead MultiSpot  
Left Ventricular  Pacing  Does  Not Improve  Acute  Hemodynamic  Response  To Conventional  
Biventricular  Pacing.  A Multicenter  Prospective,  Interventional,  Non-Randomized Study.  PLoS  One,  
2016.  11(4): p. e0154024.  
 
 
18. Appendices  
 
 
18.1 Informed  Consent  Template  
Patient informed consent form  templates will  be provided under  separate  cover.  
 
18.2 Data  Collection  Elements  (Electronic Case  Report  Forms)  
Electronic Case  Report Forms  for the  CSPOT  study  will  be provided under separate  cover. Final  eCRFs  
will  be provided to  sites via  the  electronic data  management  system  after  the  site  has  fulfilled all  
requirements  for database  access.  
18.[ADDRESS_290002] of participating investigators  and institutions  (including names,  titles/professional  
positions, address(es), and telephone numbers)  where  study  activities will  be conducted will  be 
distributed under a  separate  cover when available. Approval  of the  CSPOT Study  CIP  will  be 
documented  by [CONTACT_239106] a separate  investigator agreement.  
 
18.[ADDRESS_290003] of participating IRBs and the  Chairperson(s)  will  be provided under separate  cover.  
This  information  will  be updated throughout the  course  of the  study. The  updated list will  be 
maintained at  Medtronic and will  be available  upon  request.  
18.5 Committees  
The  CSPOT study  will  utilize  an Event Adjudication  Committee  (CEC)  for the  assessment  of all  
procedure  and system  related AEs, All  SAEs,  Cardiovascular  related  AEs  and AEs  with  a fatal  outcome.  
The  CSPOT study  may utilize  a Publication  Committee  aiming to  manage  study  publications.  
A Dat a Monitoring Committee  (DMC) is not  needed  for this  study.  This  decision  was  made  based on  
the  following criteria: it is  felt  there  are  no additional  benefits  of a DMC  reviewing  the  data in addition  to 
the  Event Adjudication  Committee  (CEC)  
The  updated member lists  will  be maintained at Medtronic and will  be made  available  upon  request.  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -202 2 Page  84 of 88  
  
18.6 Labeling  
Labeling for  the  CSPOT investigational  components will  be provided under separate  cover. Labeling for  
all system  components used  in this  study  can  be found with  each  package  insert  and/or  will  be available  
on http://manuals.medtronic.com.  
 
 
18.[ADDRESS_290004]  (FAL)  
The  information provided in this  section  pertains  to foreseeable  adverse  events  that  may be observed  in 
the  CSPOT  Feasibility  Study  and may collectively  assist  in identifying those  events  for a given  device  
or therapy  that  are  unexpected  in nature.  The  foreseeable  adverse  events  information consists of 
three  parts:  1) observed  adverse  system  effect(s)  in comparable  Medtronic  studies,  2) adverse  
events  reported  in published literature,  and3)  additional  foreseeable  adverse  events.  An evaluation  
of potentially anticipated  events  observed  in previous  clinical studies  and  reported  events in 
literature  may be used  in combination  with  device  labeling,  manuals,  current  event reporting  
information,  and other  published  data  to assess  for an unexpected  occurrence.  
The  implementation  of the  CSPOT  Research  System  involves  surgery,  therefore,  standard  adverse  
events  associated  with  a surgical  procedure  may be experienced  (e.g., anesthesia  complications,  
injury,  infections,  bleeding,  exacerbation  of pre -existing  conditions,  healing  complications,  etc.).  
However,  the  focus  of this  section  is to address  in more  detail,  those  events  that  are  foreseeable due  
to the  implementation,  use,  performance,  and/or  presence  of the  system  under  investigation.  
Potential  risks  as sociated  with  the  implementation  of the  CSPOT  Research  System  as well  as risk  
minimization  are  discussed  within  Section  11.1  and 11.2.   Treatment  required  for procedure  and/or  
system  related  adverse  events  may include  medication,  system  reprogramming,  system  
modification  (e.g., repositioning,  surgical  abandonment,  surgical  removal),  or other  surgical  and 
medical  remedies.  
 
18.7.[ADDRESS_290005] analysis.  Review/analysis  activities  
included confirmation  of appropriate  content in  the  labelling and specifications  of individual  
components.   Benchtop testing activities  included checking  the  connections, use  and 
performance  of the  individual  components  into  a functional  system.  No adverse  effects  or 
malfunctioning were  discovered.  
The  CSPOT Research  System  facilitates  the  interconnection between pacing devices  and 
permanently  implanted  leads  targeting selected  pacing locations  in the  patient’s right  and/or  left  
ventricle.  It increas es the  safety  of the  patient while  undergoing the  procedure and determines the  
CSPOT timing -intervals  used  for the  chronic study.  A comparable setup  has  been used  in previous  
MDT  studies  without any  pacing delivery  complications (iSPOT study: Clinical  Trial  Registration:  
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 29-Apr -202 2 Page  85 of 88  
  
NTC01883141  and SYNSEQ study: Clinical  Trial  Registration: NTC 02914457).  In total  62 patients 
were  included with  successful  protocol  execution  and data  collection. [ 15] 
Foreseeable  or potential  adverse  events  and patient complications  associated  with  the  acute  use  of 
the  implanted  system  the  implementation  or use  of the  CSPOT  Research  System  have  been  
identified  through  the  hazard  analysis.  The  hazard  analysis  is composed of a review of  previous  MDT  
studies  and literature to compi[INVESTIGATOR_239012].  The  
CSPOT Research  System  Hazard Analysis  Log – D00329642_C.  provides an overview  of additional  
foreseeable events,  mitigations,  conservative  estimates of incidence  rates,  hazardous  situations,  
derived  from  adverse  event  data  from  previous  Medtronic  clinical  studies  and literature  around the  
components/use of the  CSPOT system.  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 2-Apr -[ADDRESS_290006]  of the  change  on 
performance,  effectiveness,  or 
safety or other endpoints  
 
 
 
Identification  of the  affected study  
documents  
 
 
 
Author(s)/Title  
1.0  N/A  - First  Version  
release  N/A  N/A  N/A  Rachael Rose,  Pr 
Clinical  Research  
Specialist  
 
Richard  Cornelussen,  
Pr. Scientist  
 
Robert  Stadler,  Sr. 
Distinguished  
Scientist  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 2-Apr -[ADDRESS_290007]  of 
the  change  on 
performance,  
effectiveness,  or 
safety or other  
endpoints  
 
Identification  of the  
affected  study  
documents  
 
 
Author(s)/Title  
2.0  Updated language  to section  
11.1:  
 
• The  protocol  procedures  
may  take  up to [ADDRESS_290008]  
CRT  procedure time  
which  includes  up to 10 
minutes of additional  
fluoroscopy  exposure.  
• The  lead implant  
configurations for  this study  
are considered  
investigational  and  have  not  
been  studied for  MRI  use.  
Therefore, the  MRI  
conditional  labeling will  not  
apply  for these  patients.  
Updates in Section  4.1: 
 
• His Pacing  updated to His  
Bundle  Pacing  
• CV+LV  updated to CSP +LV  
 
 
Deletion  in 10.4 of the  language:  (or 
the  subject’s authorized/designated  
representative  or guardian)  
 
Table  5: updated Component  
column to reflect Medtronic  
Defibrillation  Leads in respect  to 
the  RV defib  leads  
 
Table  6 (also  reflective  in section  3 
Synopsis):  Implant  (occur within  30 
days prior  to enrollment)  update  to 
Implant  (occur within  30 days after  
to enrollment)  • Clarification  to describe  
in more  detail  protocol  
procedure time  and  
additional  risk  for lead  
implant  configurations  
 
• Grammatical  and  
language  updates  
needed  for consistency.  N/A  Master  Informed  
Consent  
Template V1  
dated  
8-Mar -[ADDRESS_290009]  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 2-Apr -[ADDRESS_290010]  of the  change  on 
performance,  effectiveness,  or 
safety or other endpoints  
 
 
 
Identification  of the  affected study  
documents   
 
 
Author(s)/Title  
3.0  • Increase number  of 
sites from 8 to 12 
• Updated  language  in 
Exclusion  criteria to:  
Subject  has  
complex  or repaired 
congenital  heart 
disease  Allow  for the  study  to 
include  more  sites if 
needed  to meet  total  
number  of patients within  
the  study  timeframe  
 
Updating  exclusion  criteria 
for better  clarification  N/A  N/A  Rachael Rose,  Pr 
Clinical  Research  
Specialist  
 
Richard  Cornelussen,  
Pr. Scientist  
 
Robert  Stadler,  Sr. 
Distinguished  
Scientist  
CSPOT  (Conduction  System  Pacing  Optimized  
Therapy)  Clinical  Investigation  Plan Form  
Version    4.0, 2-Apr -202 2 Page  89 of 88 
This document  is electronically  controlled  Medtronic Business Restricted  056-F275, vB Clinical  Investigation  Plan Template   
 4.0  • Updated Secondary 
Objectives  to 
measure  
improvement relative to baseline  
• Update to language in Section 10. 6.[ADDRESS_290011] 
LVcs electrode that 
was us ed during the 
acute testing to also 
be used for chronic programming unless phrenic nerve 
stimulation, lead 
dislodgement or high capture threshold occur  
• Updates to methods for statistical 
analysis in Section 
14.4 and 14.5 to 
Primary objectives 1 & 2 as well as 
secondary objectives 1, 2, & 5  
 • Aligns with 
method for statistical analysis  
• Adjustment 
created for 
flexibility to 
ensure 
continued patient safety  
• Aligns more with the study statistical analysi s plan   N/A  N/A  Rachael Rose,  Pr 
Clinical  Research  
Specialist  
 
Richard  Cornelussen,  
Pr. Scientist  
 
Robert  Stadler,  
Sr. 
Distinguished  
Scientist  
 
Patrick 
Zimmerman, Pr. 
Statistician  
 